Biotech catalyst calendar.
This calendar lists dated biotech events drawn from United States government records: regulatory actions the FDA has taken, advisory committee meetings noticed in the Federal Register, and trial completion dates sponsors have filed with ClinicalTrials.gov. It is rebuilt once a day, it is free, and every row links to the document it came from. Each row states how firm its date is, because most forward dates in biotech are estimates a company filed with a registry rather than commitments anyone has made.
Compiled . Methodology Recent changes Subscribe CSV JSON
Lane
Confidence
912 rows shown
Week of 28 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Eddingpharm (Zhuhai) Co. | As of 20 May 2026, Eddingpharm (Zhuhai) Co. estimated primary completion of a Phase 2 trial in Homozygous Familial Hypercholesterolemia (HoFH), on 4 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07489209 |
Week of 5 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | ModernaTX | As of 6 May 2026, ModernaTX estimated primary completion of a Phase 2 trial in Epstein-Barr Virus Infection, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05164094 | |
| Clinical | Swedish Orphan Biovitrum | As of 30 April 2026, Swedish Orphan Biovitrum estimated primary completion of a Phase 3 trial in Primary Myelofibrosis, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03165734 | |
| Clinical | UCB Biopharma SRL | As of 25 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06149559 | |
| Clinical | Bristol-Myers Squibb | As of 24 March 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis, on 6 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06003426 | |
| Moved from 15 Oct 2026 | Clinical | AstraZeneca | As of 1 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in RSV Respiratory Syncytial Virus, on 7 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07717840 |
| Clinical | Regeneron Pharmaceuticals | As of 29 May 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 7 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02612454 | |
| Clinical | Hoffmann-La Roche | As of 10 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 8 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05805501 | |
| Clinical | Incyte | As of 8 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06958211 | |
| Clinical | Incyte | As of 28 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06959225 | |
| FDA | Not named in the source | FDA approved Hovilpri (pritelivir) on 9 October 2026. | Confirmed | FDA novel drug approvals table: 2026:Hovilpri | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 23 June 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Plaque Psoriasis, on 10 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07357831 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 25 September 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 10 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07193459 | |
| Clinical | Biocodex | As of 18 November 2025, Biocodex estimated primary completion of a Phase 3 trial in IBS (Irritable Bowel Syndrome), on 11 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07168434 |
Week of 12 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 5 September 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05372354 | |
| Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Metastatic Castrate-sensitive Prostate Cancer, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05884398 | |
| Clinical | Regeneron Pharmaceuticals | As of 30 April 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05133531 | |
| Clinical | Aspa Therapeutics | As of 17 April 2026, Aspa Therapeutics estimated primary completion of a Phase 2 trial in Canavan Disease, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04998396 | |
| Clinical | Daewoong Pharmaceutical Co. | As of 16 July 2026, Daewoong Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05389215 | |
| Clinical | GlaxoSmithKline | As of 12 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in melanoma, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06521567 | |
| Clinical | Shanghai JMT-Bio | As of 24 March 2025, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06846437 | |
| Clinical | Hoffmann-La Roche | As of 25 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Unresectable Hepatocellular Carcinoma, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04770896 | |
| Clinical | Inozyme Pharma | As of 10 August 2026, Inozyme Pharma estimated primary completion of a Phase 3 trial in Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07473973 | |
| Clinical | Sanofi | As of 20 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06834347 | |
| Clinical | Birch BioMed | As of 4 May 2026, Birch BioMed estimated primary completion of a Phase 3 trial in Burn Scar, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06807021 | |
| Clinical | CanariaBio | As of 1 April 2026, CanariaBio estimated primary completion of a Phase 2 trial in Ovarian Neoplasm Epithelial, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05605535 | |
| Clinical | Eccogene | As of 25 June 2026, Eccogene estimated primary completion of a Phase 2 trial in Adult Obesity, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07505303 | |
| Clinical | Eclipse Life Sciences | As of 15 September 2026, Eclipse Life Sciences estimated primary completion of a Phase 2 trial in Diabetic Macular Edema, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06536491 | |
| Moved from 11 Nov 2026 | Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Ischemic Stroke; Ischemic Attack, Transient, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05702034 |
| Clinical | Novartis Pharmaceuticals | As of 22 September 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration Resistant Prostate Cancer (mCRPC), on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06894511 | |
| Clinical | Solid Biosciences | As of 10 August 2026, Solid Biosciences estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03368742 | |
| Clinical | Suzhou Alphamab Co. | As of 17 September 2025, Suzhou Alphamab Co. estimated primary completion of a Phase 3 trial in Hemophilia A Without Inhibitor, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06569108 | |
| Clinical | Hoffmann-La Roche | As of 2 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Non-Hodgkins Lymphoma, on 16 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03533283 | |
| Clinical | Kunming Pharmaceuticals | As of 12 December 2025, Kunming Pharmaceuticals estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 18 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07279493 |
Week of 19 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 2 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05620407 | |
| Clinical | Bristol-Myers Squibb | As of 3 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05617677 | |
| Moved from 31 Oct 2026 | Clinical | Hoffmann-La Roche | As of 10 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Breast Cancer, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05852691 |
| Clinical | Incyte | As of 28 May 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06516952 | |
| Clinical | Incyte | As of 14 April 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06516965 | |
| Clinical | Pfizer | As of 4 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Atopic Dermatitis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05995964 | |
| Clinical | Biogen | As of 9 October 2026, Biogen estimated primary completion of a Phase 3 trial in Subacute Cutaneous Lupus Erythematosus, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05531565 | |
| Clinical | Bioray Laboratories | As of 21 July 2026, Bioray Laboratories estimated primary completion of a Phase 2 trial in beta-Thalassemia, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05577312 | |
| Clinical | Daiichi Sankyo | As of 29 September 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05875168 | |
| Clinical | LEO Pharma | As of 7 July 2026, LEO Pharma estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06311682 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 11 September 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06049290 | |
| Clinical | Otsuka Pharmaceutical Development & Commercialization | As of 5 October 2026, Otsuka Pharmaceutical Development & Commercialization estimated primary completion of a Phase 3 trial in schizophrenia, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06894212 | |
| Clinical | Amgen | As of 8 January 2026, Amgen estimated primary completion of a Phase 3 trial in Sjögren's Syndrome (SS), on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06245408 | |
| Clinical | Hoffmann-La Roche | As of 23 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Progressive Multiple Sclerosis (PMS), on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03523858 | |
| Moved from 22 Sept 2026 | Clinical | Merck Sharp & Dohme | As of 20 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05468697 |
| Clinical | Shanghai Henlius Biotech | As of 20 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06812260 | |
| Clinical | AstraZeneca | As of 29 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in obesity/Overweight, on 23 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07017179 | |
| Clinical | AstraZeneca | As of 2 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 23 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06008093 |
Week of 26 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | CSL Behring | As of 23 April 2026, CSL Behring estimated primary completion of a Phase 3 trial in Congenital Hemophilia A, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06738485 | |
| Clinical | Galderma R&D | As of 12 November 2025, Galderma R&D estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04204616 | |
| Clinical | Novartis Pharmaceuticals | As of 5 October 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Coronary Artery Disease, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05360446 | |
| Clinical | AstraZeneca | As of 24 August 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 27 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05775159 | |
| Clinical | Akeso | As of 12 March 2025, Akeso estimated primary completion of a Phase 3 trial in NSCLC (Non-small Cell Lung Cancer), on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06617416 | |
| Clinical | Albireo, an Ipsen | As of 1 October 2026, Albireo, an Ipsen estimated primary completion of a Phase 3 trial in Biliary Atresia, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05426733 | |
| Clinical | Boehringer Ingelheim | As of 14 May 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Macular Degeneration, Age-related, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06722157 | |
| Clinical | Hoffmann-La Roche | As of 9 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy (SMA), on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05115110 | |
| Clinical | Merck Sharp & Dohme | As of 15 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05239728 | |
| Moved from 30 Jan 2027 | Clinical | Hoffmann-La Roche | As of 2 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Moderately to Severely Active Ulcerative Colitis, on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06588855 |
| Clinical | Merck Sharp & Dohme | As of 6 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04736706 | |
| Clinical | Novartis Pharmaceuticals | As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05653349 | |
| Clinical | RECORDATI GROUP | As of 17 September 2026, RECORDATI GROUP estimated primary completion of a Phase 2 trial in Post-Bariatric Hypoglycemia, on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05928390 | |
| Clinical | Abbisko Therapeutics Co | As of 12 August 2024, Abbisko Therapeutics Co estimated primary completion of a Phase 2 trial in cGvHD, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06186804 | |
| Clinical | Antelope Surgical Solutions | As of 29 September 2026, Antelope Surgical Solutions estimated primary completion of a Phase 2 trial in Prostate Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06906471 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 31 March 2026, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in Chronic Hepatitis B With Hepatic Fibrosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07343778 | |
| Clinical | Biotheus | As of 11 March 2025, Biotheus estimated primary completion of a Phase 2 trial in tNBC, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05918133 | |
| Clinical | CSPC Ouyi Pharmaceutical Co. | As of 6 April 2026, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07026968 | |
| Clinical | Genzyme, a Sanofi | As of 10 July 2026, Genzyme, a Sanofi estimated primary completion of a Phase 2 trial in Gaucher Disease Type 1, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02843035 | |
| Clinical | Innervate Radiopharmaceuticals | As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Heart Failure, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06965621 | |
| Clinical | Innervate Radiopharmaceuticals | As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Parkinson Disease (PD), on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07176286 | |
| Clinical | Kind Pharmaceuticals | As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07494409 | |
| Clinical | Laekna | As of 2 April 2026, Laekna estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04851613 | |
| Moved from 30 Nov 2026 | Clinical | Mirati Therapeutics | As of 14 August 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05853575 |
| Clinical | Natureceuticals Sdn Bhd | As of 25 August 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07669467 | |
| Clinical | Nouscom SRL | As of 13 February 2026, Nouscom SRL estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04041310 | |
| Clinical | Pfizer | As of 3 September 2026, Pfizer estimated primary completion of a Phase 3 trial in melanoma, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04657991 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 2 March 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Unresectable or Metastatic Breast Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06679036 | |
| Clinical | Shanghai Henlius Biotech | As of 17 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Solid Tumor Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06848699 | |
| Clinical | Tyligand Pharmaceuticals (Suzhou) | As of 24 April 2026, Tyligand Pharmaceuticals (Suzhou) estimated primary completion of a Phase 2 trial in Malignant Neoplasm, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06385925 | |
| Clinical | Vertex Pharmaceuticals Incorporated | As of 9 October 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Cystic Fibrosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05444257 | |
| Clinical | Vidya Therapeutics | As of 21 July 2026, Vidya Therapeutics estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07085507 | |
| Clinical | Vincentage Pharma Co. | As of 21 September 2026, Vincentage Pharma Co. estimated primary completion of a Phase 2 trial in hypertension, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07360275 | |
| FDA | Not named in the source | An FDA advisory committee meets on 30 October 2026 to review NDA 219694. | Confirmed | Federal Register document: 2026-19700 | |
| Clinical | Adagene | As of 7 January 2026, Adagene estimated primary completion of a Phase 2 trial in Advanced/Metastatic Solid Tumors, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05405595 | |
| Clinical | Amgen | As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in MTAP-deleted NSCLC, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06593522 | |
| Clinical | Animuscure | As of 3 August 2026, Animuscure estimated primary completion of a Phase 2 trial in Sarcopenia in Elderly, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07072195 | |
| Clinical | Annexon | As of 4 May 2026, Annexon estimated primary completion of a Phase 3 trial in Geographic Atrophy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06510816 | |
| Clinical | AskBio | As of 3 December 2025, AskBio estimated primary completion of a Phase 2 trial in Congestive Heart Failure, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05598333 | |
| Clinical | AstraZeneca | As of 17 August 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06635447 | |
| Clinical | Avistone Biotechnology Co. | As of 21 May 2025, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06574347 | |
| Clinical | Changzhou Qianhong Bio-pharma Co. | As of 9 February 2026, Changzhou Qianhong Bio-pharma Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07396337 | |
| Clinical | Freya Biosciences ApS | As of 3 September 2026, Freya Biosciences ApS estimated primary completion of a Phase 2 trial in Vaginal Dysbiosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07453069 | |
| Clinical | Genentech | As of 28 September 2026, Genentech estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06524375 | |
| Clinical | Genentech | As of 27 August 2026, Genentech estimated primary completion of a Phase 2 trial in Neoplasm Metastasis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT00781612 | |
| Clinical | Hoffmann-La Roche | As of 5 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03178552 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 13 December 2024, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06083207 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 1 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04842617 | |
| Clinical | Kadence Bio | As of 12 August 2026, Kadence Bio estimated primary completion of a Phase 2 trial in Premature Ejaculation, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07434271 | |
| Clinical | LaNova Medicines | As of 3 September 2026, LaNova Medicines estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05518045 | |
| Clinical | Longboard Pharmaceuticals | As of 15 September 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06719141 | |
| Clinical | MaaT Pharma | As of 27 December 2024, MaaT Pharma estimated primary completion of a Phase 2 trial in Transplant Complication, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05762211 | |
| Clinical | Myosin Therapeutics | As of 14 April 2026, Myosin Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma (GBM), on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07185880 | |
| Clinical | NEXTGEN Bioscience | As of 13 April 2026, NEXTGEN Bioscience estimated primary completion of a Phase 2 trial in Alopecia Areata, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06104839 | |
| Clinical | Natureceuticals Sdn Bhd | As of 25 June 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07669454 | |
| Clinical | Neurimmune | As of 7 October 2026, Neurimmune estimated primary completion of a Phase 2 trial in Amyloid Transthyretin Cardiomyopathy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07213583 | |
| Clinical | Olema Pharmaceuticals | As of 13 August 2026, Olema Pharmaceuticals estimated primary completion of a Phase 3 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06016738 | |
| Clinical | Orion Corporation, Orion Pharma | As of 14 August 2026, Orion Corporation, Orion Pharma estimated primary completion of a Phase 2 trial in Prostate Cancer Metastatic, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03436485 | |
| Clinical | Rhythm Pharmaceuticals | As of 12 February 2026, Rhythm Pharmaceuticals estimated primary completion of a Phase 2 trial in Prader-Willi Syndrome, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06772597 | |
| Clinical | Salubris Biotherapeutics | As of 22 May 2026, Salubris Biotherapeutics estimated primary completion of a Phase 2 trial in Heart Failure With Reduced Ejection Fraction, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06369298 | |
| Clinical | Sarepta Therapeutics | As of 27 February 2026, Sarepta Therapeutics estimated primary completion of a Phase 3 trial in Muscular Dystrophy, Duchenne, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03992430 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 25 November 2024, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06222879 | |
| Clinical | Shanghai Henlius Biotech | As of 10 March 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Carcinoma, Hepatocellular, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06742892 | |
| Clinical | Shanghai Henlius Biotech | As of 18 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Esophageal Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06769113 | |
| Clinical | Spyre Therapeutics | As of 5 June 2026, Spyre Therapeutics estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07148414 | |
| Clinical | TG Therapeutics | As of 21 September 2026, TG Therapeutics estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07211633 | |
| Clinical | Takeda | As of 25 February 2026, Takeda estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02716116 | |
| Clinical | Takeda | As of 30 March 2026, Takeda estimated primary completion of a Phase 3 trial in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04129502 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 8 October 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06052267 | |
| Clinical | Topadur Pharma | As of 1 October 2026, Topadur Pharma estimated primary completion of a Phase 2 trial in Digital Ulcers in Systemic Sclerosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06954597 | |
| Moved from 30 Sept 2026 | Clinical | UCB Biopharma SRL | As of 29 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05077904 |
| Clinical | Xentria | As of 2 October 2026, Xentria estimated primary completion of a Phase 2 trial in Pulmonary Sarcoidosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05890729 | |
| Clinical | AbbVie | As of 14 August 2025, AbbVie estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05822752 | |
| Clinical | AbbVie | As of 17 June 2026, AbbVie estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder (GAD), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06846320 | |
| Clinical | AbbVie | As of 28 October 2025, AbbVie estimated primary completion of a Phase 2 trial in High Grade Ovarian Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05456685 | |
| Clinical | AbbVie | As of 9 February 2026, AbbVie estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia (CLL), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04895436 | |
| Clinical | Acesion Pharma | As of 12 June 2026, Acesion Pharma estimated primary completion of a Phase 2 trial in Atrial Fibrillation (AF), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07267949 | |
| Clinical | Admetsys | As of 30 July 2024, Admetsys estimated primary completion of a Phase 2 trial in hyperglycemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT01291719 | |
| Clinical | Akeso | As of 24 June 2024, Akeso estimated primary completion of a Phase 3 trial in Gastric and Gastroesophageal Junction Adenocarcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06341335 | |
| Clinical | Alkermes | As of 25 September 2026, Alkermes estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06843590 | |
| Clinical | Anbogen Therapeutics | As of 24 June 2024, Anbogen Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05532696 | |
| Clinical | Apogee Therapeutics | As of 6 October 2026, Apogee Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06395948 | |
| Clinical | Aptose Biosciences | As of 26 August 2025, Aptose Biosciences estimated primary completion of a Phase 2 trial in Leukemia, Myeloid, Acute, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT03850574 | |
| Clinical | Arthrosi Therapeutics | As of 15 May 2026, Arthrosi Therapeutics estimated primary completion of a Phase 2 trial in gout, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07116746 | |
| Clinical | Atossa Therapeutics | As of 8 July 2026, Atossa Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05607004 | |
| Clinical | Avistone Biotechnology Co. | As of 20 March 2026, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07336732 | |
| Clinical | BeOne Medicines | As of 28 September 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04973605 | |
| Clinical | BeOne Medicines | As of 9 July 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06637501 | |
| Clinical | Beckley Psytech | As of 6 July 2026, Beckley Psytech estimated primary completion of a Phase 2 trial in Treatment Resistant Depression, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05660642 | |
| Clinical | BeiGene | As of 10 July 2026, BeiGene estimated primary completion of a Phase 2 trial in MSI-H/dMMR Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT03736889 | |
| Clinical | Bexion Pharmaceuticals | As of 29 September 2026, Bexion Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Colorectal Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05322590 | |
| Clinical | BioNTech SE | As of 7 October 2026, BioNTech SE estimated primary completion of a Phase 2 trial in Colorectal Cancer Stage II, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04486378 | |
| Clinical | Bristol-Myers Squibb | As of 22 September 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06951698 | |
| Clinical | CG Oncology | As of 1 July 2026, CG Oncology estimated primary completion of a Phase 3 trial in Non Muscle Invasive Bladder Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06111235 | |
| Clinical | Calluna Pharma AS | As of 27 April 2026, Calluna Pharma AS estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06736990 | |
| Clinical | Camurus | As of 28 July 2026, Camurus estimated primary completion of a Phase 3 trial in Gastro-enteropancreatic Neuroendocrine Tumor, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05050942 | |
| Clinical | Cardiff Oncology | As of 16 June 2026, Cardiff Oncology estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06106308 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. | As of 19 September 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Pancreatic Neoplasms, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06767813 | |
| Clinical | Colgate Palmolive | As of 27 May 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in Plaque, Dental, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07605338 | |
| Clinical | Corbus Pharmaceuticals | As of 3 June 2025, Corbus Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06603844 | |
| Clinical | DBV Technologies | As of 22 July 2026, DBV Technologies estimated primary completion of a Phase 3 trial in allergy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07003919 | |
| Clinical | Eli Lilly and | As of 1 May 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Acute Pain, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07511816 | |
| Clinical | Eli Lilly and | As of 13 July 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07215312 | |
| Clinical | Eli Lilly and | As of 17 February 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06962280 | |
| Clinical | Eli Lilly and | As of 29 September 2025, Eli Lilly and estimated primary completion of a Phase 3 trial in oSA, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06649045 | |
| Clinical | Eli Lilly and | As of 12 May 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06914895 | |
| Clinical | Eli Lilly and | As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06662383 | |
| Clinical | Epygenix | As of 9 October 2026, Epygenix estimated primary completion of a Phase 3 trial in Lennox Gastaut Syndrome, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05066217 | |
| Clinical | Erasca | As of 22 June 2026, Erasca estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04866134 | |
| Clinical | Ferrer Internacional | As of 15 October 2025, Ferrer Internacional estimated primary completion of a Phase 2 trial in Progressive Supranuclear Palsy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06355531 | |
| Clinical | Forge Biologics | As of 2 June 2026, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04693598 | |
| Clinical | Forge Biologics | As of 20 November 2025, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05739643 | |
| Clinical | Gilead Sciences | As of 28 September 2026, Gilead Sciences estimated primary completion of a Phase 3 trial in hIV-1-infection, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06532656 | |
| Clinical | IGC Pharma | As of 30 September 2026, IGC Pharma estimated primary completion of a Phase 2 trial in Alzheimer Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05543681 | |
| Clinical | Immunic | As of 1 October 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05134441 | |
| Clinical | Immunic | As of 1 October 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, Relapsing-Remitting, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05201638 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 12 March 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Local Analgesia Via Nerve Block, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06529432 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 5 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in HER2-expressing Advanced Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06015048 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 23 September 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06569056 | |
| Clinical | KeyBioscience | As of 19 February 2025, KeyBioscience estimated primary completion of a Phase 2 trial in Osteoarthritis in the Knee, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06833749 | |
| Clinical | Kiora Pharmaceuticals | As of 9 September 2026, Kiora Pharmaceuticals estimated primary completion of a Phase 2 trial in Macular Edema, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06825702 | |
| Clinical | LG Chem | As of 3 July 2025, LG Chem estimated primary completion of a Phase 3 trial in diphtheria, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06947499 | |
| Clinical | Lynk Pharmaceuticals Co. | As of 20 November 2025, Lynk Pharmaceuticals Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07237568 | |
| Clinical | ML Bio Solutions | As of 21 July 2026, ML Bio Solutions estimated primary completion of a Phase 2 trial in lGMD2I, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04800874 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 26 November 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in nSCLC, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06107686 | |
| Clinical | Medicure | As of 16 October 2025, Medicure estimated primary completion of a Phase 3 trial in Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04706013 | |
| Clinical | NeuShen Therapeutics | As of 13 April 2026, NeuShen Therapeutics estimated primary completion of a Phase 2 trial in schizophrenia(Acute), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07521683 | |
| Clinical | NewAmsterdam Pharma | As of 4 June 2024, NewAmsterdam Pharma estimated primary completion of a Phase 3 trial in Atherosclerotic Cardiovascular Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05202509 | |
| Clinical | NewAmsterdam Pharma | As of 9 April 2026, NewAmsterdam Pharma estimated primary completion of a Phase 2 trial in dyslipidemias, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06496243 | |
| Clinical | Nuance Hearing | As of 15 December 2025, Nuance Hearing estimated primary completion of a Phase 3 trial in Hearing Loss Mixed, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07282028 | |
| Clinical | Pacira Pharmaceuticals | As of 25 August 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 2 trial in Osteoarthritis (OA) of the Knee, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06884865 | |
| Clinical | Pharmazz | As of 31 December 2025, Pharmazz estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05514340 | |
| Clinical | Pharming Technologies B.V. | As of 13 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Primary Immunodeficiency Disorders (PIDs), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06549114 | |
| Moved from 30 Aug 2026 | Clinical | ReCode Therapeutics | As of 19 August 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06237335 |
| Clinical | Reunion Neuroscience | As of 15 September 2026, Reunion Neuroscience estimated primary completion of a Phase 2 trial in Adjustment Disorder, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07002034 | |
| Clinical | SK Life Science | As of 9 September 2026, SK Life Science estimated primary completion of a Phase 3 trial in Partial Epilepsy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05067634 | |
| Clinical | Sandoz | As of 29 May 2026, Sandoz estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06847724 | |
| Clinical | Scholar Rock | As of 1 September 2026, Scholar Rock estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05626855 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 31 August 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Primary Aldosteronism, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07470983 | |
| Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. | As of 27 March 2026, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in Seasonal Allergic Rhinitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07398859 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Nasopharyngeal Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06118333 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06668961 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06448312 | |
| Clinical | Sinovac Biotech Co. | As of 10 August 2026, Sinovac Biotech Co. estimated primary completion of a Phase 3 trial in Epidemic Meningitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07505888 | |
| Clinical | Stemline Therapeutics | As of 7 May 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05596409 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 9 January 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Malignant Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06737731 | |
| Clinical | Suzhou Zelgen Biopharmaceuticals Co. | As of 5 January 2026, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05584800 | |
| Moved from 1 Dec 2026 | Clinical | TBF Genie Tissulaire | As of 6 October 2026, TBF Genie Tissulaire estimated primary completion of a Phase 2 trial in Osteoarthritis Hand, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06038331 |
| Clinical | Tyra Biosciences | As of 12 January 2026, Tyra Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced Urothelial Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05544552 | |
| Clinical | Vir Biotechnology | As of 16 January 2026, Vir Biotechnology estimated primary completion of a Phase 2 trial in Viral Hepatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07142811 | |
| Clinical | Waterstone Pharmaceutical (Wuhan) Co. | As of 26 November 2025, Waterstone Pharmaceutical (Wuhan) Co. estimated primary completion of a Phase 3 trial in hyperkalemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07251309 | |
| Clinical | Wooshin Labottach Co. | As of 26 January 2026, Wooshin Labottach Co. estimated primary completion of a Phase 3 trial in Nail Psoriasis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07029516 | |
| Clinical | Xentria | As of 21 August 2026, Xentria estimated primary completion of a Phase 2 trial in Pulmonary Sarcoidosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06169397 | |
| Clinical | Zura Bio | As of 30 June 2026, Zura Bio estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa (HS), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06993610 | |
| Clinical | argenx | As of 25 September 2025, argenx estimated primary completion of a Phase 2 trial in dermatomyositis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06284954 | |
| Clinical | medac | As of 27 August 2025, medac estimated primary completion of a Phase 3 trial in Moderate to Severe Atopic Dermatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06239311 |
Week of 2 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AstraZeneca | As of 29 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Cutaneous Lupus Erythematosus, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06015737 | |
| Clinical | Bristol-Myers Squibb | As of 24 September 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06951711 | |
| Clinical | GlaxoSmithKline | As of 26 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Rectal, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05723562 | |
| Clinical | Keymed Biosciences Co. | As of 9 April 2026, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Chronic Spontaneous Urticaria (CSU), on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07166211 | |
| Clinical | Regeneron Pharmaceuticals | As of 10 February 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in melanoma, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06190951 | |
| Moved from 19 Sept 2026 | Clinical | Teva Branded Pharmaceutical Products R&D | As of 6 October 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06664619 |
| Clinical | Novartis Pharmaceuticals | As of 2 October 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, on 3 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05677451 | |
| Clinical | CMG Pharmaceutical Co. | As of 15 January 2026, CMG Pharmaceutical Co. estimated primary completion of a Phase 3 trial in dyslipidemia, on 4 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06772168 | |
| Clinical | AstraZeneca | As of 2 October 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Prostate Cancer, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07336446 | |
| Clinical | Genzyme, a Sanofi | As of 17 December 2025, Genzyme, a Sanofi estimated primary completion of a Phase 3 trial in hemophilia, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03754790 | |
| Clinical | Incyte | As of 25 June 2026, Incyte estimated primary completion of a Phase 2 trial in B-Cell Malignancies, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04509700 | |
| Clinical | Sanofi | As of 2 June 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 6 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06834360 |
Week of 9 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bio-Thera Solutions | As of 13 August 2025, Bio-Thera Solutions estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 9 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06376136 | |
| Clinical | GlaxoSmithKline | As of 15 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Lung Cancer, Non-Small Cell, on 9 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05565378 | |
| Clinical | Gan & Lee Pharmaceuticals. | As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in diabetes, on 10 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07165223 | |
| Clinical | HELP Therapeutics Co. | As of 10 February 2026, HELP Therapeutics Co. estimated primary completion of a Phase 2 trial in Heart Failure, on 10 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06340048 | |
| Clinical | AstraZeneca | As of 30 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer; HER2-positive; Metastatic, on 11 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04784715 | |
| Clinical | Precigen | As of 23 April 2026, Precigen estimated primary completion of a Phase 2 trial in Cervical Cancer, on 11 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06157151 | |
| Clinical | Qilu Pharmaceutical Co. | As of 2 February 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Heavy Menstrual Bleeding, on 12 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06671548 | |
| Clinical | AstraZeneca | As of 27 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia (B-ALL), on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06137118 | |
| Clinical | Hoffmann-La Roche | As of 28 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Breast Cancer, on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05646862 | |
| Clinical | Regeneron Pharmaceuticals | As of 2 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04626635 | |
| Clinical | Regeneron Pharmaceuticals | As of 17 June 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Overweight or Obesity, on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07431086 | |
| Clinical | PolyActiva Pty | As of 8 July 2026, PolyActiva Pty estimated primary completion of a Phase 2 trial in Glaucoma, Open-Angle, on 15 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06964191 |
Week of 16 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Merck Sharp & Dohme | As of 20 January 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa, on 16 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06956235 | |
| Clinical | UCB Biopharma SRL | As of 2 October 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 16 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06055959 | |
| Clinical | AstraZeneca | As of 30 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastric Cancer, on 17 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06219941 | |
| Clinical | Bristol-Myers Squibb | As of 1 April 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Sjögren's Syndrome, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05946941 | |
| Clinical | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | As of 10 June 2026, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in Prostate Cancer, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03348670 | |
| Moved from 26 Aug 2026 | Clinical | Hoffmann-La Roche | As of 4 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06450639 |
| Clinical | Medicine Invention Design | As of 8 October 2026, Medicine Invention Design estimated primary completion of a Phase 3 trial in ALK-Positive Non-Small Cell Lung Cancer (NSCLC), on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05987956 | |
| Clinical | ToLymph | As of 24 September 2026, ToLymph estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06693336 | |
| Clinical | Hoffmann-La Roche | As of 12 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 19 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06402838 | |
| Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 2 trial in Dermatitis, Atopic, on 19 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07230860 | |
| Clinical | Incyte | As of 7 July 2026, Incyte estimated primary completion of a Phase 2 trial in Moderate to Severe Asthma, on 20 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05851443 | |
| Moved from 15 Sept 2026 | Clinical | Merck Sharp & Dohme | As of 18 September 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Endometrial Neoplasms, on 20 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04634877 |
| Clinical | Skye Bioscience | As of 14 January 2026, Skye Bioscience estimated primary completion of a Phase 2 trial in obesity, on 20 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06577090 | |
| Clinical | Changchun GeneScience Pharmaceutical Co. | As of 2 October 2025, Changchun GeneScience Pharmaceutical Co. estimated primary completion of a Phase 3 trial in hyperprolactinemia, on 21 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07124221 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 28 May 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Pain After Surgery, on 22 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07533786 | |
| Clinical | Shanghai Henlius Biotech | As of 24 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Nasopharyngeal Carcinoma (NPC), on 22 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06839066 |
Week of 23 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Moved from 11 Dec 2026 | Clinical | GlaxoSmithKline | As of 8 September 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 23 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07596199 |
| Clinical | GlaxoSmithKline | As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 23 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06693895 | |
| Clinical | GlaxoSmithKline | As of 22 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Colon, on 23 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06567782 | |
| Clinical | AstraZeneca | As of 23 February 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Metastatic Prostate Cancer, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06267729 | |
| Clinical | CanSino Biologics | As of 5 August 2026, CanSino Biologics estimated primary completion of a Phase 2 trial in Streptococcus Pneumoniae Infection, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07600983 | |
| Moved from 21 Aug 2026 | Clinical | EMD Serono Research & Development Institute | As of 22 September 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 3 trial in Solid Tumors, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03815643 |
| Clinical | HTA Co. | As of 10 July 2025, HTA Co. estimated primary completion of a Phase 3 trial in NETS Ga68 Lu177, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07057622 | |
| Clinical | Karuna Therapeutics, Inc., a Bristol Myers Squibb | As of 22 September 2026, Karuna Therapeutics, Inc., a Bristol Myers Squibb estimated primary completion of a Phase 3 trial in Alzheimer Disease, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06585787 | |
| Clinical | Tectonic Therapeutic | As of 7 July 2026, Tectonic Therapeutic estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06616974 | |
| Clinical | Beijing InnoCare Pharma Tech Co. | As of 8 September 2025, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 25 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06775860 | |
| Clinical | Shaanxi Micot Pharmaceutical Technology Co. | As of 1 October 2025, Shaanxi Micot Pharmaceutical Technology Co. estimated primary completion of a Phase 3 trial in Secondary Hyperparathyroidism, Chronic Kidney Disease, on 26 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07122401 | |
| Clinical | Tesaro | As of 3 September 2025, Tesaro estimated primary completion of a Phase 3 trial in neoplasms, on 26 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03981796 | |
| Clinical | Hoffmann-La Roche | As of 7 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Type 2 Diabetes Mellitus, on 27 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07112872 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 28 October 2024, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Non-cystic Fibrosis Bronchiectasis, on 28 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06660992 | |
| Clinical | TrueBinding | As of 23 April 2026, TrueBinding estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD), on 28 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06773962 | |
| Clinical | Pfizer | As of 9 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Menstrual Migraine, on 29 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06641466 |
Week of 30 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AUG Therapeutics | As of 1 May 2026, AUG Therapeutics estimated primary completion of a Phase 3 trial in Leukocyte Adhesion Deficiency, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05462587 | |
| Clinical | Amgen | As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in Advanced MTAP-null Solid Tumors, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05094336 | |
| Clinical | Arvinas | As of 16 September 2026, Arvinas estimated primary completion of a Phase 2 trial in KRAS G12D Mutation, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07023731 | |
| Clinical | AstraZeneca | As of 12 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07081633 | |
| Clinical | Aura Biosciences | As of 8 October 2026, Aura Biosciences estimated primary completion of a Phase 2 trial in Eye Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06643884 | |
| Clinical | Bavarian Nordic | As of 8 April 2026, Bavarian Nordic estimated primary completion of a Phase 2 trial in monkeypox (Mpox), on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07199569 | |
| Clinical | BeyondBio | As of 10 March 2025, BeyondBio estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05093907 | |
| Clinical | BeyondBio | As of 10 March 2025, BeyondBio estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Pancreatic Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03579836 | |
| Clinical | Bio-Thera Solutions | As of 2 October 2026, Bio-Thera Solutions estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06341114 | |
| Clinical | BioAge Labs | As of 10 September 2026, BioAge Labs estimated primary completion of a Phase 2 trial in Obesity and Cardiovascular Risk, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07656727 | |
| Clinical | Celgene | As of 29 November 2024, Celgene estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03989414 | |
| Clinical | Cytopeutics Sdn. Bhd. | As of 2 January 2026, Cytopeutics Sdn. Bhd. estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06129175 | |
| Clinical | Genentech | As of 10 September 2026, Genentech estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04302025 | |
| Clinical | Gritgen Therapeutics Co. | As of 9 December 2025, Gritgen Therapeutics Co. estimated primary completion of a Phase 3 trial in Hemophilia A, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06833983 | |
| Moved from 31 Dec 2026 | Clinical | Hoffmann-La Roche | As of 8 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03148418 |
| Clinical | Immunocore | As of 28 January 2026, Immunocore estimated primary completion of a Phase 2 trial in cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06840119 | |
| Clinical | InventisBio Co. | As of 31 March 2026, InventisBio Co. estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06954961 | |
| Clinical | ModernaTX | As of 15 December 2025, ModernaTX estimated primary completion of a Phase 2 trial in Glycogen Storage Disease, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05095727 | |
| Clinical | Mundipharma Research | As of 14 May 2026, Mundipharma Research estimated primary completion of a Phase 2 trial in Chronic Pulmonary Aspergillosis, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06794554 | |
| Clinical | Mylan Pharmaceuticals | As of 26 January 2026, Mylan Pharmaceuticals estimated primary completion of a Phase 2 trial in contraception, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07365904 | |
| Clinical | Neonc Technologies | As of 14 September 2026, Neonc Technologies estimated primary completion of a Phase 2 trial in Glioblastoma Multiforme, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT02704858 | |
| Clinical | NeuroPace | As of 15 September 2026, NeuroPace estimated primary completion of a Phase 2 trial in epilepsy, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05339126 | |
| Clinical | OncoC4 | As of 22 May 2026, OncoC4 estimated primary completion of a Phase 2 trial in Metastatic Castration-resistant Prostate Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05682443 | |
| Clinical | OriCell Therapeutics Co. | As of 31 May 2024, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Relapsed and/or Refractory Multiple Myeloma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06182696 | |
| Clinical | Pharming Technologies B.V. | As of 6 May 2026, Pharming Technologies B.V. estimated primary completion of a Phase 3 trial in aPDS, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05438407 | |
| Clinical | Ranok Therapeutics (Hangzhou) Co. | As of 24 December 2025, Ranok Therapeutics (Hangzhou) Co. estimated primary completion of a Phase 2 trial in KRAS G12D Mutations, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07303465 | |
| Clinical | Sanofi | As of 6 November 2025, Sanofi estimated primary completion of a Phase 3 trial in Immune Thrombocytopenia, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07216079 | |
| Clinical | Saol Therapeutics | As of 25 August 2026, Saol Therapeutics estimated primary completion of a Phase 3 trial in Osteoarthritis Knee Pain, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07226258 | |
| Clinical | Shanghai JMT-Bio | As of 18 August 2026, Shanghai JMT-Bio estimated primary completion of a Phase 2 trial in Unresectable Locally Advanced or Metastatic Melanoma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07280832 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06968585 | |
| Clinical | Taisho Pharmaceutical Co. | As of 6 October 2026, Taisho Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodialysis, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07548840 | |
| Clinical | Takeda | As of 8 October 2026, Takeda estimated primary completion of a Phase 2 trial in Narcolepsy Type 2, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06952699 | |
| Clinical | Takeda | As of 15 July 2026, Takeda estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06812078 | |
| Clinical | Tolmar | As of 29 September 2026, Tolmar estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04906395 | |
| Clinical | UniQure Biopharma B.V. | As of 24 August 2026, UniQure Biopharma B.V. estimated primary completion of a Phase 2 trial in Mesial Temporal Lobe Epilepsy, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06063850 | |
| Clinical | Verdiva Bio Dev | As of 4 August 2026, Verdiva Bio Dev estimated primary completion of a Phase 2 trial in obesity, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07553299 | |
| Clinical | Zhejiang Wenda Pharma Technology | As of 29 June 2026, Zhejiang Wenda Pharma Technology estimated primary completion of a Phase 3 trial in Moderate to Severe Plaque Psoriasis, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07672561 | |
| Clinical | 3D Medicines (Sichuan) Co. | As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Advanced Endometrial Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05112991 | |
| Clinical | 3D Medicines (Sichuan) Co. | As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05024214 | |
| Clinical | 858 Therapeutics | As of 27 March 2026, 858 Therapeutics estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06395519 | |
| Clinical | A2 Biotherapeutics | As of 25 April 2025, A2 Biotherapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05736731 | |
| Clinical | AP Biosciences | As of 26 March 2025, AP Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05473156 | |
| Clinical | AP Biosciences | As of 25 April 2025, AP Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06669975 | |
| Clinical | ASTEROGENE Biomedical Co. | As of 3 April 2026, ASTEROGENE Biomedical Co. estimated primary completion of a Phase 2 trial in Intervertebral Disc Degeneration, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07168603 | |
| Clinical | Aadi Bioscience | As of 13 November 2025, Aadi Bioscience estimated primary completion of a Phase 2 trial in Endometrial Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05997017 | |
| Clinical | AbbVie | As of 2 September 2026, AbbVie estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06468228 | |
| Clinical | AbbVie | As of 12 December 2025, AbbVie estimated primary completion of a Phase 2 trial in Unresectable Metastatic Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06107413 | |
| Clinical | AbbVie | As of 19 September 2025, AbbVie estimated primary completion of a Phase 2 trial in Irritable Bowel Syndrome, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03339128 | |
| Clinical | AbbVie | As of 28 April 2026, AbbVie estimated primary completion of a Phase 3 trial in aMD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04704921 | |
| Clinical | Abivax | As of 27 April 2026, Abivax estimated primary completion of a Phase 2 trial in Moderately to Severely Active Crohn Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06456593 | |
| Clinical | Adicet Therapeutics | As of 10 September 2026, Adicet Therapeutics estimated primary completion of a Phase 2 trial in Clear Cell Renal Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06480565 | |
| Clinical | Akeso | As of 16 March 2026, Akeso estimated primary completion of a Phase 3 trial in Triple-Negative Breast Cancer (TNBC), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06767527 | |
| Clinical | Akeso | As of 3 June 2025, Akeso estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer Stage IIIB/IV, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06943820 | |
| Clinical | Akeso | As of 18 March 2026, Akeso estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05689853 | |
| Clinical | Aldeyra Therapeutics | As of 11 February 2026, Aldeyra Therapeutics estimated primary completion of a Phase 3 trial in Primary Vitreoretinal Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07402876 | |
| Clinical | Alkeus Pharmaceuticals | As of 27 April 2025, Alkeus Pharmaceuticals estimated primary completion of a Phase 2 trial in Stargardt Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04239625 | |
| Clinical | Allist Pharmaceuticals | As of 13 August 2026, Allist Pharmaceuticals estimated primary completion of a Phase 3 trial in Non-small Cell Lung Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04853342 | |
| Clinical | Alto Neuroscience | As of 24 July 2025, Alto Neuroscience estimated primary completion of a Phase 2 trial in Major Depressive Disorder, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05922878 | |
| Clinical | Alyssum Therapeutics | As of 23 July 2026, Alyssum Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06234098 | |
| Clinical | Alzamend Neuro | As of 28 July 2026, Alzamend Neuro estimated primary completion of a Phase 2 trial in Bipolar I Disorder, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07540338 | |
| Clinical | Ambrx | As of 9 March 2026, Ambrx estimated primary completion of a Phase 2 trial in HER2 Positive Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04829604 | |
| Clinical | Amydis | As of 13 February 2026, Amydis estimated primary completion of a Phase 2 trial in Cerebral Amyloid Angiopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05709314 | |
| Clinical | Angitia Biopharmaceuticals | As of 10 February 2026, Angitia Biopharmaceuticals estimated primary completion of a Phase 2 trial in Postmenopausal Osteoporosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06577935 | |
| Clinical | Ascentage Pharma Group | As of 27 March 2026, Ascentage Pharma Group estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05147467 | |
| Clinical | Astria Therapeutics | As of 30 June 2026, Astria Therapeutics estimated primary completion of a Phase 3 trial in Hereditary Angioedema (HAE), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06842823 | |
| Clinical | Atea Pharmaceuticals | As of 29 June 2026, Atea Pharmaceuticals estimated primary completion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07037277 | |
| Clinical | Avalyn Pharma | As of 10 August 2026, Avalyn Pharma estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07194382 | |
| Clinical | Aveta Biomics | As of 16 January 2026, Aveta Biomics estimated primary completion of a Phase 2 trial in Head and Neck Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05312710 | |
| Clinical | Axsome Therapeutics | As of 28 July 2026, Axsome Therapeutics estimated primary completion of a Phase 3 trial in Binge-Eating Disorder, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06413433 | |
| Clinical | Axsome Therapeutics | As of 24 July 2026, Axsome Therapeutics estimated primary completion of a Phase 3 trial in Excessive Sleepiness, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06568367 | |
| Clinical | Beam Therapeutics | As of 13 January 2025, Beam Therapeutics estimated primary completion of a Phase 2 trial in Lymphoblastic Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05885464 | |
| Clinical | Beijing Scitech-Mq Pharmaceuticals | As of 24 August 2025, Beijing Scitech-Mq Pharmaceuticals estimated primary completion of a Phase 2 trial in Unresectable or Metastatic Melanoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06359860 | |
| Clinical | BioCardia | As of 12 December 2025, BioCardia estimated primary completion of a Phase 2 trial in Heart Failure, Systolic, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05925608 | |
| Clinical | BioRestorative Therapies | As of 26 August 2025, BioRestorative Therapies estimated primary completion of a Phase 2 trial in Lumbar Disc Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04042844 | |
| Clinical | Biocomposites | As of 6 May 2026, Biocomposites estimated primary completion of a Phase 2 trial in Pressure Ulcer, Stage IV, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06283979 | |
| Clinical | Biogen | As of 5 June 2026, Biogen estimated primary completion of a Phase 3 trial in Antibody-mediated Rejection, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06685757 | |
| Clinical | Biohaven Therapeutics | As of 30 September 2026, Biohaven Therapeutics estimated primary completion of a Phase 3 trial in Focal Epilepsy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06132893 | |
| Clinical | Biohaven Therapeutics | As of 1 May 2026, Biohaven Therapeutics estimated primary completion of a Phase 2 trial in Focal Epilepsy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06443463 | |
| Clinical | Bivision Pharmaceuticals | As of 9 October 2026, Bivision Pharmaceuticals estimated primary completion of a Phase 2 trial in Prostate Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06139575 | |
| Clinical | Brii Biosciences | As of 30 December 2024, Brii Biosciences estimated primary completion of a Phase 2 trial in For Treatment of Chronic Hepatitis B Virus Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06491563 | |
| Clinical | COUR Pharmaceutical Development Company | As of 11 September 2026, COUR Pharmaceutical Development Company estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06783309 | |
| Clinical | Cancer Vaccines | As of 20 January 2026, Cancer Vaccines estimated primary completion of a Phase 2 trial in cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03096093 | |
| Clinical | Cartesian Therapeutics | As of 27 March 2026, Cartesian Therapeutics estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus (SLE), on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06038474 | |
| Clinical | CellARTs | As of 24 February 2025, CellARTs estimated primary completion of a Phase 2 trial in Infertility, Male, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06841861 | |
| Clinical | Celltrion | As of 11 August 2025, Celltrion estimated primary completion of a Phase 3 trial in t2DM, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07093476 | |
| Clinical | Centessa Pharmaceuticals (UK) | As of 27 April 2026, Centessa Pharmaceuticals (UK) estimated primary completion of a Phase 2 trial in Narcolepsy Type 1, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06752668 | |
| Clinical | Chengdu Kangnuoxing Biopharma | As of 3 September 2026, Chengdu Kangnuoxing Biopharma estimated primary completion of a Phase 3 trial in Seasonal Allergic Rhinitis (SAR), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07678931 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 12 March 2024, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06202261 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 8 December 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in myelofibrosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06122831 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 11 March 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Biliary Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05987358 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 20 February 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocellular Carcinoma (HCC), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04344158 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 17 April 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05780567 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. | As of 26 August 2024, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-alcoholic Steatohepatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06569524 | |
| Clinical | CivaTech Oncology | As of 4 April 2025, CivaTech Oncology estimated primary completion of a Phase 2 trial in Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03290534 | |
| Clinical | Compass Therapeutics | As of 7 May 2026, Compass Therapeutics estimated primary completion of a Phase 3 trial in Biliary Tract Cancer, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05506943 | |
| Clinical | Connect Biopharm | As of 27 August 2026, Connect Biopharm estimated primary completion of a Phase 2 trial in Asthma Acute, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07705737 | |
| Clinical | Cook MyoSite | As of 21 July 2026, Cook MyoSite estimated primary completion of a Phase 3 trial in Fecal Incontinence, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05776277 | |
| Clinical | Corcept Therapeutics | As of 9 October 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Cushing Syndrome, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03604198 | |
| Clinical | Delcath Systems | As of 1 June 2026, Delcath Systems estimated primary completion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06607458 | |
| Clinical | Denali Therapeutics | As of 15 January 2026, Denali Therapeutics estimated primary completion of a Phase 2 trial in Frontotemporal Dementia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05262023 | |
| Clinical | Design Therapeutics | As of 18 May 2025, Design Therapeutics estimated primary completion of a Phase 2 trial in Friedreich Ataxia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06874010 | |
| Clinical | DiaMedica Therapeutics | As of 14 September 2026, DiaMedica Therapeutics estimated primary completion of a Phase 3 trial in Acute Stroke, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05065216 | |
| Clinical | Dianthus Therapeutics | As of 10 August 2026, Dianthus Therapeutics estimated primary completion of a Phase 2 trial in Multifocal Motor Neuropathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06537999 | |
| Clinical | Dizal Pharmaceuticals | As of 31 December 2025, Dizal Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06295432 | |
| Clinical | Dogwood Therapeutics | As of 16 September 2026, Dogwood Therapeutics estimated primary completion of a Phase 2 trial in Chemotherapy Induced Neuropathic Pain, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06848348 | |
| Clinical | Dr. Falk Pharma | As of 28 August 2026, Dr. Falk Pharma estimated primary completion of a Phase 3 trial in Eosinophilic Esophagitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06596252 | |
| Clinical | Dren Bio | As of 17 June 2026, Dren Bio estimated primary completion of a Phase 2 trial in LGLL - Large Granular Lymphocytic Leukemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05475925 | |
| Clinical | EicOsis Human Health | As of 10 July 2026, EicOsis Human Health estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07142044 | |
| Clinical | Eikon Therapeutics | As of 28 May 2026, Eikon Therapeutics estimated primary completion of a Phase 2 trial in nSCLC, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06246110 | |
| Clinical | Eli Lilly and | As of 21 August 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Type 2 Diabetes, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06897475 | |
| Clinical | Eli Lilly and | As of 8 October 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in nausea, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07169851 | |
| Clinical | Elion Therapeutics | As of 5 October 2026, Elion Therapeutics estimated primary completion of a Phase 2 trial in Invasive Mould Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07215273 | |
| Clinical | Elixiron Immunotherapeutics | As of 9 June 2026, Elixiron Immunotherapeutics estimated primary completion of a Phase 2 trial in Mild, Moderate, or Severe Alzheimer's Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06745583 | |
| Clinical | Enanta Pharmaceuticals | As of 20 July 2026, Enanta Pharmaceuticals estimated primary completion of a Phase 2 trial in RSV Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07482657 | |
| Clinical | Enveda Therapeutics | As of 25 September 2026, Enveda Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis (AD), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07298395 | |
| Clinical | Enveda Therapeutics | As of 24 September 2026, Enveda Therapeutics estimated primary completion of a Phase 2 trial in asthma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07301255 | |
| Clinical | EpicentRx | As of 26 June 2026, EpicentRx estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04673942 | |
| Clinical | Eupraxia Pharmaceuticals | As of 19 March 2026, Eupraxia Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05608681 | |
| Clinical | FindCure Biosciences (ZhongShan) Co. | As of 4 September 2026, FindCure Biosciences (ZhongShan) Co. estimated primary completion of a Phase 2 trial in Advanced Malignant Solid Tumors, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06499350 | |
| Clinical | Frantz Viral Therapeutics | As of 14 August 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Vulvar Diseases, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06075264 | |
| Clinical | Fujian Akeylink Biotechnology Co. | As of 23 January 2026, Fujian Akeylink Biotechnology Co. estimated primary completion of a Phase 3 trial in Chronic Hepatitis b, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07090759 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 17 November 2025, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Bstructive Sleep Apnea (OSA) and Obesity, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06974851 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 31 July 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Mild to Moderate Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07297797 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 26 January 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06994650 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 26 August 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Prevention of Postoperative Nausea and Vomiting, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07709897 | |
| Clinical | GC Cell | As of 22 November 2021, GC Cell estimated primary completion of a Phase 3 trial in Pancreatic Ductal Adenocarcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04969731 | |
| Clinical | GE Healthcare | As of 6 May 2026, GE Healthcare estimated primary completion of a Phase 2 trial in Myocardial Ischemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04604782 | |
| Clinical | Galderma R&D | As of 27 July 2026, Galderma R&D estimated primary completion of a Phase 2 trial in Chronic Pruritus of Unknown Origin, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07074977 | |
| Clinical | GeneCradle | As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy Type 3, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06421831 | |
| Clinical | GeneCradle | As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Pompe Disease (Late-onset), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06391736 | |
| Clinical | GeneCradle | As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05824169 | |
| Clinical | Genelux | As of 26 August 2026, Genelux estimated primary completion of a Phase 3 trial in Platinum-resistant Ovarian Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05281471 | |
| Clinical | Georgiamune | As of 14 August 2026, Georgiamune estimated primary completion of a Phase 2 trial in Melanoma Stage IV, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06425926 | |
| Clinical | Gilead Sciences | As of 9 February 2026, Gilead Sciences estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04639986 | |
| Clinical | Gossamer Bio USA | As of 29 July 2026, Gossamer Bio USA estimated primary completion of a Phase 3 trial in Pulmonary Arterial Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06274801 | |
| Clinical | Grand Shuyang Life Sciences (Chengdu) Co. | As of 8 April 2026, Grand Shuyang Life Sciences (Chengdu) Co. estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07233213 | |
| Clinical | Guangdong Hengrui Pharmaceutical Co. | As of 17 August 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Seasonal Allergic Rhinitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07688772 | |
| Clinical | Guangzhou Gloria Biosciences Co. | As of 18 June 2023, Guangzhou Gloria Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05909436 | |
| Clinical | Harrow | As of 22 September 2026, Harrow estimated primary completion of a Phase 3 trial in Postoperative Ocular Inflammation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07832552 | |
| Clinical | Henan Genuine Biotech Co. | As of 6 January 2026, Henan Genuine Biotech Co. estimated primary completion of a Phase 2 trial in HIV-1 Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07308782 | |
| Clinical | Heron Neutron Medical | As of 9 July 2026, Heron Neutron Medical estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07691775 | |
| Clinical | Highlight Therapeutics | As of 17 September 2026, Highlight Therapeutics estimated primary completion of a Phase 2 trial in Basal Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06422936 | |
| Clinical | Imbria Pharmaceuticals | As of 18 May 2026, Imbria Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-obstructive Hypertrophic Cardiomyopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07023614 | |
| Moved from 1 Oct 2026 | Clinical | Ingenia Therapeutics | As of 7 October 2026, Ingenia Therapeutics estimated primary completion of a Phase 2 trial in Healthy Volunteers, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07231679 |
| Clinical | Inmunotek S.L. | As of 13 May 2025, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis, Allergic, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04435990 | |
| Clinical | Institut de Recherches Internationales Servier | As of 25 February 2026, Institut de Recherches Internationales Servier estimated primary completion of a Phase 2 trial in ALL, Adult, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06052813 | |
| Clinical | Intra-IMMUSG Pte | As of 22 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04452955 | |
| Clinical | Intra-IMMUSG Pte | As of 16 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 3 trial in Advanced Solid Cancers, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07290088 | |
| Clinical | Ionis Pharmaceuticals | As of 12 December 2025, Ionis Pharmaceuticals estimated primary completion of a Phase 3 trial in Hereditary Angioedema, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05392114 | |
| Clinical | Iperboreal Pharma Srl | As of 16 May 2025, Iperboreal Pharma Srl estimated primary completion of a Phase 2 trial in Congestive Heart Failure, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03994874 | |
| Clinical | Italfarma | As of 30 April 2025, Italfarma estimated primary completion of a Phase 2 trial in Chronic Myeloproliferative Neoplasms, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT01761968 | |
| Clinical | JYAMS PET Research & Development | As of 20 February 2026, JYAMS PET Research & Development estimated primary completion of a Phase 3 trial on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07422857 | |
| Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Prostatic Neoplasms, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03767244 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 20 April 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05482568 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 19 May 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Advanced Gastroenteropancreatic Neuroendocrine Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05884255 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 12 June 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06974929 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 17 September 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Prostate Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06568094 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 4 June 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07472725 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 17 July 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06507436 | |
| Clinical | K-Group, Beta | As of 29 September 2026, K-Group, Beta estimated primary completion of a Phase 2 trial on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05128825 | |
| Clinical | Kardigan | As of 30 September 2026, Kardigan estimated primary completion of a Phase 2 trial in hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07511361 | |
| Clinical | Karyopharm Therapeutics | As of 1 October 2026, Karyopharm Therapeutics estimated primary completion of a Phase 2 trial in Diffuse Large B-cell Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT02227251 | |
| Clinical | Karyopharm Therapeutics | As of 2 October 2026, Karyopharm Therapeutics estimated primary completion of a Phase 3 trial in Relapsed/Refractory Diffuse Large B-cell Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04442022 | |
| Clinical | Kedrion S.p.A. | As of 29 May 2026, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Primary Immunodeficiency Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04944979 | |
| Clinical | Kedrion S.p.A. | As of 11 September 2026, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Chronic Primary Immune Thrombocytopenia (ITP), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07059000 | |
| Clinical | Keymed Biosciences Co. | As of 15 October 2024, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05299424 | |
| Clinical | Kind Pharmaceuticals | As of 27 February 2026, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in Myelodysplastic Syndromes, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06304103 | |
| Clinical | Kind Pharmaceuticals | As of 27 February 2026, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in β -Thalassemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06302491 | |
| Clinical | Kind Pharmaceuticals | As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07487727 | |
| Clinical | Kite, A Gilead | As of 11 February 2026, Kite, A Gilead estimated primary completion of a Phase 2 trial in Multiple Myeloma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05396885 | |
| Clinical | Krystal Biotech | As of 12 March 2026, Krystal Biotech estimated primary completion of a Phase 3 trial in Dystrophic Epidermolysis Bullosa, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07016750 | |
| Clinical | Krystal Biotech | As of 27 February 2026, Krystal Biotech estimated primary completion of a Phase 2 trial in Neurotrophic Keratitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06999733 | |
| Clinical | LaNova Medicines | As of 2 May 2025, LaNova Medicines estimated primary completion of a Phase 2 trial in Malignant Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06650566 | |
| Clinical | Lamassu Bio | As of 9 September 2026, Lamassu Bio estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06578624 | |
| Clinical | Lantern Pharma | As of 4 May 2026, Lantern Pharma estimated primary completion of a Phase 2 trial in Adenocarcinoma of Lung, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05456256 | |
| Clinical | Latticon Antibody Therapeutics | As of 8 July 2025, Latticon Antibody Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06277219 | |
| Clinical | Lexeo Therapeutics | As of 12 November 2025, Lexeo Therapeutics estimated primary completion of a Phase 2 trial in Arrhythmogenic Cardiomyopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06109181 | |
| Clinical | Lumicell | As of 16 January 2026, Lumicell estimated primary completion of a Phase 2 trial in Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT02584244 | |
| Clinical | Luxa Biotechnology | As of 15 October 2025, Luxa Biotechnology estimated primary completion of a Phase 2 trial in Dry Age-related Macular Degeneration, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04627428 | |
| Clinical | Mabscale | As of 16 August 2024, Mabscale estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05654454 | |
| Clinical | Mabwell (Shanghai) Bioscience Co. | As of 8 May 2026, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in scar, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07576608 | |
| Clinical | Madrigal Pharmaceuticals | As of 8 July 2026, Madrigal Pharmaceuticals estimated primary completion of a Phase 3 trial in nASH, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05500222 | |
| Clinical | MediWound | As of 9 October 2026, MediWound estimated primary completion of a Phase 3 trial in Venous Leg Ulcer (VLU), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06568627 | |
| Clinical | Meribank Biotech Co. | As of 15 July 2024, Meribank Biotech Co. estimated primary completion of a Phase 2 trial in Pathologic Processes, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06501066 | |
| Clinical | Minghui Pharmaceutical (Hangzhou) | As of 9 October 2026, Minghui Pharmaceutical (Hangzhou) estimated primary completion of a Phase 3 trial in Thyroid Associated Ophthalmopathies, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06989918 | |
| Clinical | Minovia Therapeutics | As of 22 June 2025, Minovia Therapeutics estimated primary completion of a Phase 2 trial in Mitochondrial Diseases, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06017869 | |
| Clinical | NKGen Biotech | As of 2 July 2026, NKGen Biotech estimated primary completion of a Phase 2 trial in Moderate Alzheimer Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06189963 | |
| Clinical | NMD Pharma | As of 21 August 2026, NMD Pharma estimated primary completion of a Phase 2 trial in Myasthenia Gravis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06414954 | |
| Clinical | NS Pharma | As of 26 May 2026, NS Pharma estimated primary completion of a Phase 2 trial in Eosinophilic Granulomatosis With Polyangiitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06046222 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 30 June 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05170958 | |
| Clinical | Napo Pharmaceuticals | As of 9 June 2026, Napo Pharmaceuticals estimated primary completion of a Phase 3 trial in Microvillus Inclusion Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06721871 | |
| Clinical | Newsoara HYK Biopharmaceutical (Shanghai) Co. | As of 3 December 2025, Newsoara HYK Biopharmaceutical (Shanghai) Co. estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07136285 | |
| Clinical | Nexcella | As of 14 July 2026, Nexcella estimated primary completion of a Phase 2 trial in Light Chain (AL) Amyloidosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06097832 | |
| Clinical | Next Life Sciences | As of 6 October 2026, Next Life Sciences estimated primary completion of a Phase 2 trial in fertility, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07361120 | |
| Clinical | NoNO | As of 15 July 2025, NoNO estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06403267 | |
| Clinical | Octapharma | As of 29 September 2026, Octapharma estimated primary completion of a Phase 3 trial in Acute Hereditary Angio Edema, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06361537 | |
| Clinical | Octapharma | As of 28 September 2026, Octapharma estimated primary completion of a Phase 3 trial in Congenital Antithrombin Deficiency, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04918173 | |
| Clinical | Oculis | As of 28 August 2026, Oculis estimated primary completion of a Phase 3 trial in Dry Eye Disease (DED), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07548632 | |
| Clinical | Omeros | As of 16 July 2026, Omeros estimated primary completion of a Phase 2 trial in Paroxysmal Nocturnal Hemoglobinuria, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06298955 | |
| Clinical | One-carbon Therapeutics | As of 28 January 2026, One-carbon Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07151040 | |
| Clinical | OriCell Therapeutics Co. | As of 3 April 2024, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05652920 | |
| Clinical | PT. Prodia Stem Cell Indonesia | As of 27 February 2026, PT. Prodia Stem Cell Indonesia estimated primary completion of a Phase 2 trial in Acute Respiratory Distress Syndrome, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07439848 | |
| Clinical | Pacira Pharmaceuticals | As of 29 May 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 3 trial in Glenohumeral Osteoarthritis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06269705 | |
| Clinical | Panafina | As of 5 August 2026, Panafina estimated primary completion of a Phase 2 trial in Acute Pancreatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06080789 | |
| Clinical | Phoenix Molecular Designs | As of 16 July 2026, Phoenix Molecular Designs estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04115306 | |
| Clinical | Praxis Precision Medicines | As of 4 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy 1, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07010471 | |
| Clinical | Praxis Precision Medicines | As of 3 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Epileptic Encephalopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07019922 | |
| Clinical | Priovant Therapeutics | As of 18 May 2025, Priovant Therapeutics estimated primary completion of a Phase 2 trial in Cutaneous Sarcoidosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06978725 | |
| Clinical | Protara Therapeutics | As of 24 August 2026, Protara Therapeutics estimated primary completion of a Phase 2 trial in Lymphatic Malformation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05871970 | |
| Clinical | Pulmovant | As of 20 February 2026, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06635850 | |
| Clinical | Pulmovant | As of 2 September 2026, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07333183 | |
| Clinical | Qilu Pharmaceutical Co. | As of 30 July 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hospital-acquired Bacterial Pneumonia (HABP), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07089186 | |
| Clinical | Qilu Pharmaceutical Co. | As of 2 June 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Prostate Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07198633 | |
| Clinical | Qilu Pharmaceutical Co. | As of 10 June 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in nSCLC, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06754644 | |
| Clinical | Qilu Pharmaceutical Co. | As of 22 May 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in hypertension (HTN), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07489612 | |
| Clinical | RDC Clinical Pty | As of 2 July 2026, RDC Clinical Pty estimated primary completion of a Phase 3 trial in Absorption of Omega-3, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07241377 | |
| Clinical | Ranok Therapeutics (Hangzhou) Co. | As of 30 October 2025, Ranok Therapeutics (Hangzhou) Co. estimated primary completion of a Phase 2 trial in KRAS G12D Mutation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06667544 | |
| Clinical | RayzeBio | As of 5 October 2026, RayzeBio estimated primary completion of a Phase 3 trial in gEP-NET, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05477576 | |
| Clinical | ReAlta Life Sciences | As of 24 November 2025, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Steroid Refractory GVHD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06343792 | |
| Clinical | ReAlta Life Sciences | As of 13 April 2026, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05778188 | |
| Clinical | Red de Terapia Celular | As of 24 July 2025, Red de Terapia Celular estimated primary completion of a Phase 2 trial in Lupus Nephritis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03673748 | |
| Clinical | Regenerative Ocular Immunobiologics | As of 8 July 2026, Regenerative Ocular Immunobiologics estimated primary completion of a Phase 2 trial in oGHVD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06852768 | |
| Clinical | RemeGen Co. | As of 3 April 2024, RemeGen Co. estimated primary completion of a Phase 3 trial in Gastric Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06221748 | |
| Clinical | Resolve Therapeutics | As of 18 July 2025, Resolve Therapeutics estimated primary completion of a Phase 2 trial in Primary Sjögren Syndrome, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06440525 | |
| Clinical | Rottapharm Biotech | As of 29 October 2025, Rottapharm Biotech estimated primary completion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05205330 | |
| Clinical | Ryvu Therapeutics SA | As of 17 September 2026, Ryvu Therapeutics SA estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06987058 | |
| Clinical | Ryvu Therapeutics SA | As of 18 September 2026, Ryvu Therapeutics SA estimated primary completion of a Phase 2 trial in Non-Hodgkin Lymphoma, B-cell, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06534437 | |
| Clinical | SERDA bv | As of 7 August 2026, SERDA bv estimated primary completion of a Phase 2 trial in Burn Injury, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06628037 | |
| Clinical | Sanofi | As of 18 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Obstructive Pulmonary Disease, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06208306 | |
| Clinical | Sanofi | As of 16 January 2026, Sanofi estimated primary completion of a Phase 2 trial in Pandemic Influenza Immunization, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06907511 | |
| Clinical | Sanofi Pasteur, a Sanofi | As of 6 October 2025, Sanofi Pasteur, a Sanofi estimated primary completion of a Phase 3 trial in Pneumococcal Infections, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06838000 | |
| Clinical | Sapience Therapeutics | As of 9 February 2026, Sapience Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04478279 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 26 January 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Malignant Tumour, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06915142 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 29 December 2025, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06820099 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 2 June 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07229950 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 26 January 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 3 trial in Locally Advanced Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07024173 | |
| Clinical | Shanghai BDgene Co. | As of 18 May 2025, Shanghai BDgene Co. estimated primary completion of a Phase 2 trial in Herpes Simplex Virus Type I Stromal Keratitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06474442 | |
| Clinical | Shanghai Fosun Pharmaceutical Industrial Development Co. | As of 5 March 2025, Shanghai Fosun Pharmaceutical Industrial Development Co. estimated primary completion of a Phase 2 trial in safety, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06858618 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 17 September 2026, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06605222 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 14 January 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 3 trial in Locally Advanced or Metastatic Breast Cancer, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05860465 | |
| Clinical | Shanghai Vitalgen BioPharma Co. | As of 24 December 2025, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 3 trial in Bietti Crystalline Dystrophy, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06699108 | |
| Clinical | Shanghai Yidian Pharmaceutical Technology Development Co. | As of 17 February 2026, Shanghai Yidian Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in sepsis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07413094 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Cervical Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05990803 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06006169 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignancies, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06131450 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05956587 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignant Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05803018 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 28 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05949606 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06405425 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05623982 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06066203 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06008054 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urinary System Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05785039 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 1 September 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05054439 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06042894 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 21 September 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06114511 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Triple-negative Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06471205 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05965856 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06382129 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 28 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Squamous Cell Carcinoma of Head and Neck, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05668858 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05924841 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06500026 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 8 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Her2-positive/Low-expression Urinary and Digestive Tract Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06031584 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Extensive-stage Small-cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06437509 | |
| Clinical | Sichuan Huiyu Pharmaceutical Co. | As of 29 January 2026, Sichuan Huiyu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in safety, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06243354 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 July 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06711900 | |
| Clinical | Sinew Pharma | As of 10 January 2024, Sinew Pharma estimated primary completion of a Phase 2 trial in hepatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05557448 | |
| Clinical | Songqi Gao | As of 19 December 2025, Songqi Gao estimated primary completion of a Phase 2 trial in MRI Scan, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06262139 | |
| Clinical | Sound Pharmaceuticals, Incorporated | As of 26 June 2026, Sound Pharmaceuticals, Incorporated estimated primary completion of a Phase 2 trial in Hearing Loss, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06340633 | |
| Clinical | Sound Pharmaceuticals, Incorporated | As of 13 July 2026, Sound Pharmaceuticals, Incorporated estimated primary completion of a Phase 3 trial in Meniere's Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06859788 | |
| Clinical | Stemline Therapeutics | As of 9 October 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05386108 | |
| Clinical | Step Pharma | As of 16 June 2026, Step Pharma estimated primary completion of a Phase 2 trial in Lymphoma, B-Cell, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05463263 | |
| Clinical | Sunhawk Vision Biotech | As of 23 January 2026, Sunhawk Vision Biotech estimated primary completion of a Phase 2 trial in Myopia, Progressive, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06579287 | |
| Clinical | Sunshine Lake Pharma Co. | As of 24 April 2026, Sunshine Lake Pharma Co. estimated primary completion of a Phase 2 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05139719 | |
| Clinical | Suven Life Sciences | As of 15 September 2026, Suven Life Sciences estimated primary completion of a Phase 3 trial in agitation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05397639 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 11 September 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Ovarian Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06840002 | |
| Moved from 31 Aug 2026 | Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 8 September 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in nSCLC, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06844474 |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 19 March 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06671379 | |
| Clinical | SynDevRx | As of 22 April 2026, SynDevRx estimated primary completion of a Phase 2 trial in HR+/HER2-negative Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05455619 | |
| Clinical | SynerGene Therapeutics | As of 30 May 2025, SynerGene Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Pancreatic Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT02340117 | |
| Clinical | TR Therapeutics | As of 2 April 2025, TR Therapeutics estimated primary completion of a Phase 3 trial in Venous Leg Ulcer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06707103 | |
| Clinical | TVAX Biomedical | As of 1 July 2025, TVAX Biomedical estimated primary completion of a Phase 3 trial in Glioblastoma Multiforme of Brain, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05685004 | |
| Clinical | Taiho Oncology | As of 1 September 2026, Taiho Oncology estimated primary completion of a Phase 2 trial in Advanced Cholangiocarcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05727176 | |
| Clinical | Tasly Pharmaceutical Group Co. | As of 21 November 2024, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06000956 | |
| Clinical | Tasly Pharmaceuticals | As of 9 April 2025, Tasly Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Stable Angina Pectoris, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03789552 | |
| Clinical | Technophage, SA | As of 9 September 2025, Technophage, SA estimated primary completion of a Phase 2 trial in Acute Spinal Cord Injury (SCI), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06677229 | |
| Clinical | Theralase® Technologies | As of 24 November 2025, Theralase® Technologies estimated primary completion of a Phase 2 trial in Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03945162 | |
| Clinical | TiumBio Co. | As of 30 March 2025, TiumBio Co. estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05784688 | |
| Clinical | TolerogenixX | As of 11 April 2025, TolerogenixX estimated primary completion of a Phase 2 trial in Kidney Transplantation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05365672 | |
| Clinical | Toll Biotech Co. | As of 1 October 2026, Toll Biotech Co. estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis (RA), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07408024 | |
| Clinical | TransThera Sciences (Nanjing) | As of 6 July 2026, TransThera Sciences (Nanjing) estimated primary completion of a Phase 3 trial in cholangiocarcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05948475 | |
| Clinical | Traws Pharma | As of 27 March 2026, Traws Pharma estimated primary completion of a Phase 2 trial in influenza, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07371650 | |
| Clinical | United Therapeutics | As of 6 October 2026, United Therapeutics estimated primary completion of a Phase 3 trial in pAH, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03683186 | |
| Clinical | VIS | As of 5 September 2024, VIS estimated primary completion of a Phase 3 trial in presbyopia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06487897 | |
| Clinical | Vanda Pharmaceuticals | As of 20 April 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Nausea and Vomiting, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07446439 | |
| Clinical | Vanda Pharmaceuticals | As of 17 August 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Social Anxiety Disorder (SAD), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07221578 | |
| Clinical | VapeAway | As of 7 January 2026, VapeAway estimated primary completion of a Phase 2 trial in Addiction Nicotine, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07322432 | |
| Clinical | Ventus Therapeutics U.S. | As of 5 October 2026, Ventus Therapeutics U.S. estimated primary completion of a Phase 2 trial in Cutaneous Lupus Erythematosus (CLE), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07260877 | |
| Clinical | Veradermics | As of 12 February 2026, Veradermics estimated primary completion of a Phase 3 trial in Androgenetic Alopecia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06972264 | |
| Clinical | Vergent Bioscience | As of 19 August 2026, Vergent Bioscience estimated primary completion of a Phase 3 trial in Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07499674 | |
| Clinical | Vir Biotechnology | As of 13 July 2026, Vir Biotechnology estimated primary completion of a Phase 3 trial in Viral Hepatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07128550 | |
| Clinical | Wuxi Cellular Biopharmaceutical Group | As of 16 July 2025, Wuxi Cellular Biopharmaceutical Group estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06570291 | |
| Clinical | Xenothera | As of 20 August 2026, Xenothera estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06154291 | |
| Clinical | Zenith Epigenetics | As of 8 May 2026, Zenith Epigenetics estimated primary completion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04986423 | |
| Clinical | Zhejiang Haichang Biotech Co. | As of 11 September 2026, Zhejiang Haichang Biotech Co. estimated primary completion of a Phase 2 trial in Advanced Hepatocellular Carcinoma (HCC), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06309485 | |
| Clinical | Zucara Therapeutics | As of 29 April 2026, Zucara Therapeutics estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus With Hypoglycemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05762107 | |
| Clinical | jCyte | As of 30 July 2026, jCyte estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06912633 | |
| Clinical | Pfizer | As of 25 September 2026, Pfizer estimated primary completion of a Phase 3 trial in Metastatic Castration-Resistant Prostate Cancer, on 2 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06629779 | |
| Clinical | Pfizer | As of 26 August 2026, Pfizer estimated primary completion of a Phase 3 trial in Severe Alopecia Areata, on 2 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07029711 | |
| Clinical | Eisai | As of 11 February 2026, Eisai estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 3 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06602258 | |
| Clinical | Regeneron Pharmaceuticals | As of 1 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-Transfusion Dependent Beta-Thalassemia (NTDT), on 3 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06421636 | |
| Clinical | Pfizer | As of 6 May 2026, Pfizer estimated primary completion of a Phase 3 trial in Lyme Disease, on 4 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07500506 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 1 June 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in IgA Nephropathy (IgAN), on 5 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07616700 | |
| Clinical | Suzhou Forlong Biotechnology Co. | As of 8 January 2026, Suzhou Forlong Biotechnology Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 5 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07131202 |
Week of 7 December 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Alexion Pharmaceuticals | As of 19 December 2025, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in nMOSD, on 7 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06724809 | |
| Moved from 31 Oct 2026 | Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Atrial Fibrillation, on 8 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05757869 |
| Clinical | Pfizer | As of 1 September 2026, Pfizer estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa, on 8 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07228390 | |
| Clinical | SK Bioscience Co. | As of 9 September 2026, SK Bioscience Co. estimated primary completion of a Phase 2 trial in Healthy Participants, on 9 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07280858 | |
| Clinical | AstraZeneca | As of 1 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Chronic Kidney Disease and Hypertension, on 10 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07222917 | |
| Moved from 2 Sept 2026 | Clinical | Boehringer Ingelheim | As of 1 October 2026, Boehringer Ingelheim estimated primary completion of a Phase 3 trial in Lung Cancer, Non-squamous, Non-small Cell, on 10 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06151574 |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 30 April 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 10 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05686642 | |
| Clinical | Gan & Lee Pharmaceuticals. | As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in Type 2 Diabetes Mellitus (T2DM), on 11 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06778967 | |
| Clinical | GlaxoSmithKline | As of 18 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in neoplasms, on 11 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03441113 | |
| Clinical | Seagen | As of 22 July 2026, Seagen estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, on 11 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04879329 | |
| Clinical | Ausper Biopharma Co. | As of 5 August 2026, Ausper Biopharma Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 12 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07137910 | |
| Clinical | Beijing QL Biopharmaceutical Co. | As of 12 June 2026, Beijing QL Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Overweight , Obesity, on 12 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07230132 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 28 August 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Psoriatic Arthritis, on 13 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04957550 |
Week of 14 December 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Amgen | As of 1 April 2026, Amgen estimated primary completion of a Phase 3 trial in Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), on 14 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06430866 | |
| Clinical | Bristol-Myers Squibb | As of 30 July 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Heart Failure, on 14 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06122779 | |
| Clinical | GlaxoSmithKline | As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 14 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06806137 | |
| Clinical | LEO Pharma | As of 1 October 2026, LEO Pharma estimated primary completion of a Phase 2 trial in Palmoplantar Pustulosis, on 14 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07013201 | |
| Clinical | Novartis Pharmaceuticals | As of 10 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC), on 14 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06004661 | |
| Clinical | Novo Nordisk | As of 7 May 2026, Novo Nordisk estimated primary completion of a Phase 2 trial in overweight, on 14 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07184632 | |
| Clinical | Alexion Pharmaceuticals | As of 1 April 2026, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06607627 | |
| Clinical | Cerus | As of 21 September 2026, Cerus estimated primary completion of a Phase 2 trial in Healthy Subjects, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07015437 | |
| Clinical | EXACT Therapeutics AS | As of 3 April 2026, EXACT Therapeutics AS estimated primary completion of a Phase 2 trial in Locally Advanced Pancreatic Adenocarcinoma, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06850623 | |
| Clinical | Exelixis | As of 29 July 2026, Exelixis estimated primary completion of a Phase 3 trial in Non-Clear Cell Renal Cell Carcinoma, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05678673 | |
| Clinical | GV20 Therapeutics | As of 13 February 2025, GV20 Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05669430 | |
| Clinical | Gedeon Richter | As of 8 October 2025, Gedeon Richter estimated primary completion of a Phase 3 trial in schizophrenia, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03817502 | |
| Clinical | Ipsen | As of 9 September 2026, Ipsen estimated primary completion of a Phase 3 trial in Moderate to Severe Glabellar Lines, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07427797 | |
| Clinical | Ipsen | As of 1 October 2026, Ipsen estimated primary completion of a Phase 3 trial in Moderate to Severe Glabellar Lines, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07435428 | |
| Moved from 15 Aug 2026 | Clinical | PMV Pharmaceuticals | As of 2 October 2026, PMV Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 15 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04585750 |
| Clinical | Hoffmann-La Roche | As of 8 October 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in NMDAR Autoimmune Encephalitis, on 16 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05503264 | |
| Clinical | Shanghai JMT-Bio | As of 7 July 2026, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial in Early or Locally Advanced HER2-positive Breast Cancer, on 16 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06747338 | |
| Clinical | Ipsen | As of 1 October 2026, Ipsen estimated primary completion of a Phase 3 trial in Primary Biliary Cholangitis, on 17 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06730061 | |
| Clinical | Sanofi | As of 27 March 2026, Sanofi estimated primary completion of a Phase 2 trial in Crohn's Disease, on 17 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06958536 | |
| Clinical | Sanofi | As of 9 October 2026, Sanofi estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 17 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06975722 | |
| Clinical | AbbVie | As of 19 May 2026, AbbVie estimated primary completion of a Phase 2 trial in migraine, on 18 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06602479 | |
| Clinical | Ausper Biopharma Co. | As of 4 May 2026, Ausper Biopharma Co. estimated primary completion of a Phase 3 trial in Chronic Hepatitis B, on 18 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07246889 | |
| Moved from 18 Sept 2026 | Clinical | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | As of 8 October 2026, Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair estimated primary completion of a Phase 3 trial in sCLC, on 18 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07145333 |
| Clinical | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | As of 23 April 2026, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in Breast Cancer, on 18 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06062810 | |
| Clinical | TJ Biopharma Co. | As of 20 July 2026, TJ Biopharma Co. estimated primary completion of a Phase 3 trial in Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lympho, on 20 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07208058 |
Week of 21 December 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Pfizer | As of 13 May 2026, Pfizer estimated primary completion of a Phase 3 trial in Alopecia Areata, on 21 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06873945 | |
| Clinical | UCB Biopharma SRL | As of 25 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 21 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06921850 | |
| Clinical | Adverum Biotechnologies | As of 22 May 2026, Adverum Biotechnologies estimated primary completion of a Phase 3 trial in Neovascular Age-Related Macular Degeneration (nAMD), on 22 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06856577 | |
| Moved from 25 Dec 2026 | Clinical | Boehringer Ingelheim | As of 30 September 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Geographic Atrophy, on 22 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06769048 |
| Clinical | Janssen Pharmaceutica N.V., Belgium | As of 25 September 2026, Janssen Pharmaceutica N.V., Belgium estimated primary completion of a Phase 2 trial in Alzheimer Disease, on 22 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06544616 | |
| Clinical | Taisho Pharmaceutical Co. | As of 17 April 2026, Taisho Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodialysis, on 22 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07285291 | |
| Clinical | AstraZeneca | As of 29 September 2026, AstraZeneca estimated primary completion of a Phase 3 trial in asthma, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05692180 | |
| Clinical | Changchun GeneScience Pharmaceutical Co. | As of 17 February 2026, Changchun GeneScience Pharmaceutical Co. estimated primary completion of a Phase 2 trial on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07260500 | |
| Clinical | Cho Pharma | As of 17 August 2026, Cho Pharma estimated primary completion of a Phase 2 trial in Non-Hodgkin Lymphoma, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05950165 | |
| Clinical | Corxel Pharmaceuticals | As of 28 May 2026, Corxel Pharmaceuticals estimated primary completion of a Phase 2 trial in Type II Diabetes Mellitus, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07340320 | |
| Clinical | Fusion Pharmaceuticals | As of 8 April 2026, Fusion Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration-resistant Prostate Cancer, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06402331 | |
| Clinical | Novartis Pharmaceuticals | As of 11 September 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Prostatic Neoplasm, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05849298 | |
| Clinical | OncoZenge | As of 9 September 2026, OncoZenge estimated primary completion of a Phase 3 trial in Head & Neck Cancer, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07672236 | |
| Clinical | R-Bio | As of 10 July 2023, R-Bio estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04427930 | |
| Clinical | Sanofi | As of 23 September 2026, Sanofi estimated primary completion of a Phase 2 trial in Focal Segmental Glomerulosclerosis, on 23 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06500702 | |
| Clinical | InxMed (Shanghai) Co. | As of 30 April 2025, InxMed (Shanghai) Co. estimated primary completion of a Phase 2 trial in Ovarian Cancer Recurrent, on 24 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06014528 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 27 August 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumour, on 24 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06783647 | |
| Clinical | Shanghai Kechow Pharma | As of 9 September 2026, Shanghai Kechow Pharma estimated primary completion of a Phase 3 trial in Colorectal Cancer Metastatic, on 24 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06008119 | |
| Clinical | GlaxoSmithKline | As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 25 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06740630 | |
| Clinical | Pfizer | As of 17 June 2026, Pfizer estimated primary completion of a Phase 2 trial in Chronic Spontaneous Urticaria, on 25 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07219615 | |
| Clinical | CanariaBio | As of 1 April 2026, CanariaBio estimated primary completion of a Phase 3 trial in Carcinoma, Ovarian Epithelial, on 26 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04498117 | |
| Clinical | Incyte | As of 25 August 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa (HS), on 26 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06212999 | |
| Clinical | Amplexd Therapeutics | As of 14 May 2026, Amplexd Therapeutics estimated primary completion of a Phase 2 trial in High-risk HPV (Any Strain), on 27 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07572396 | |
| Clinical | Stemline Therapeutics | As of 12 June 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Breast Cancer, on 27 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05563220 |
Week of 28 December 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Beijing InnoCare Pharma Tech Co. | As of 27 January 2022, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 2 trial in hematoma, on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05210868 | |
| Clinical | Chengdu Origen Biotechnology Co. | As of 27 November 2024, Chengdu Origen Biotechnology Co. estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration, on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05672121 | |
| Clinical | Frantz Viral Therapeutics | As of 18 May 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Anal High Grade Squamous Intraepithelial Lesion, on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05555862 | |
| Clinical | GlaxoSmithKline | As of 24 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Ovarian Neoplasms, on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04641247 | |
| Clinical | Jiangsu Topcel-KH Pharmaceutical Co. | As of 13 April 2025, Jiangsu Topcel-KH Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Crohn's Disease, on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06925594 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 12 March 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Neuroendocrine Carcinoma, on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06157827 | |
| Clinical | Pfizer | As of 11 August 2026, Pfizer estimated primary completion of a Phase 3 trial in Metastatic Castrate Resistant Prostate Cancer (mCRPC), on 28 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06551324 | |
| Clinical | Arctic Therapeutics | As of 21 July 2026, Arctic Therapeutics estimated primary completion of a Phase 2 trial in Hereditary Cystatin C Amyloid Angiopathy (HCCAA), on 29 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07716865 | |
| Clinical | Regeneron Pharmaceuticals | As of 22 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in hypercholesterolemia, on 29 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07477704 | |
| Clinical | Suzhou Sanegene Bio | As of 4 September 2026, Suzhou Sanegene Bio estimated primary completion of a Phase 2 trial in IgA Nephropathy (IgAN), on 29 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06786338 | |
| Clinical | 3D Medicines (Sichuan) Co. | As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03667170 | |
| Clinical | 4TEEN4 Pharmaceuticals | As of 14 September 2026, 4TEEN4 Pharmaceuticals estimated primary completion of a Phase 2 trial in Shock, Cardiogenic, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06832722 | |
| Clinical | Akeso | As of 16 March 2026, Akeso estimated primary completion of a Phase 2 trial in Metastatic Triple-negative Breast Cancer, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05227664 | |
| Clinical | Akeso | As of 9 March 2026, Akeso estimated primary completion of a Phase 2 trial in Metastatic Pancreatic Ductal Adenocarcinoma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06646055 | |
| Clinical | Allotera Therapeutics | As of 28 September 2026, Allotera Therapeutics estimated primary completion of a Phase 2 trial in T-cell Acute Lymphoblastic Leukemia, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06514794 | |
| Clinical | Amorphical | As of 14 August 2026, Amorphical estimated primary completion of a Phase 2 trial in hypoparathyroidism, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06547151 | |
| Clinical | AskGene Pharma | As of 16 September 2026, AskGene Pharma estimated primary completion of a Phase 3 trial in Gastroesophageal Junction Adenocarcinoma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06206733 | |
| Clinical | Astellas Pharma Global Development | As of 11 August 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pancreatic Adenocarcinoma Metastatic, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06792435 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 22 April 2026, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in Radiation-induced Lung Injury, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07388680 | |
| Clinical | Beijing Konruns Pharmaceutical Co. | As of 7 March 2024, Beijing Konruns Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Esophageal Squamous Cell Carcinoma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06194734 | |
| Clinical | Bionic Sight | As of 23 January 2026, Bionic Sight estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04278131 | |
| Clinical | CanariaBio | As of 3 April 2026, CanariaBio estimated primary completion of a Phase 2 trial in Recurrent Ovarian Cancer, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05335993 | |
| Moved from 30 Nov 2026 | Clinical | Cartesian Therapeutics | As of 1 September 2026, Cartesian Therapeutics estimated primary completion of a Phase 3 trial in Myasthaenia Gravis, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06799247 |
| Clinical | Chengdu Zenitar Biomedical Technology Co. | As of 4 February 2026, Chengdu Zenitar Biomedical Technology Co. estimated primary completion of a Phase 2 trial in Diffuse Large B Cell Lymphoma，DLBCL, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05563844 | |
| Clinical | Ever Supreme Bio Technology Co. | As of 19 September 2024, Ever Supreme Bio Technology Co. estimated primary completion of a Phase 2 trial in gBM, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04115761 | |
| Clinical | Ganzhou Hemay Pharmaceutical Co. | As of 3 April 2026, Ganzhou Hemay Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Moderate to Severe Ulcerative Colitis, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05486104 | |
| Clinical | HC Biopharma | As of 17 December 2025, HC Biopharma estimated primary completion of a Phase 2 trial in nSCLC, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07169552 | |
| Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Urinary Bladder Neoplasms, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04658862 | |
| Clinical | Janssen Research & Development | As of 25 September 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Depressive Disorder, Major, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06559306 | |
| Clinical | Jiangsu vcare pharmaceutical technology co. | As of 27 July 2026, Jiangsu vcare pharmaceutical technology co. estimated primary completion of a Phase 3 trial on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06577519 | |
| Clinical | Jiangsu vcare pharmaceutical technology co. | As of 27 July 2026, Jiangsu vcare pharmaceutical technology co. estimated primary completion of a Phase 3 trial in Locally Advanced Solid Tumor, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06658353 | |
| Clinical | L & L Bio Co., Ltd., Ningbo, China | As of 11 September 2025, L & L Bio Co., Ltd., Ningbo, China estimated primary completion of a Phase 2 trial in Solid Tumor, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06468358 | |
| Clinical | Meribank Biotech Co. | As of 8 July 2024, Meribank Biotech Co. estimated primary completion of a Phase 2 trial in Chronic Obstructive Pulmonary Disease, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06491043 | |
| Clinical | NATCO Pharma | As of 23 January 2026, NATCO Pharma estimated primary completion of a Phase 2 trial in carcinoma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05283226 | |
| Clinical | Neonc Technologies | As of 15 September 2026, Neonc Technologies estimated primary completion of a Phase 2 trial on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05023018 | |
| Clinical | Novartis Pharmaceuticals | As of 21 August 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Tuberous Sclerosis Complex, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT02962414 | |
| Clinical | Novartis Pharmaceuticals | As of 20 August 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06388941 | |
| Clinical | Pfizer | As of 9 March 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05573555 | |
| Clinical | Pfizer | As of 10 February 2026, Pfizer estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05909397 | |
| Clinical | Psyence Australia Pty | As of 3 March 2026, Psyence Australia Pty estimated primary completion of a Phase 2 trial in Adjustment Disorder, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07072728 | |
| Clinical | Quoin Pharmaceuticals | As of 31 August 2026, Quoin Pharmaceuticals estimated primary completion of a Phase 3 trial in Netherton Syndrome, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05789056 | |
| Clinical | Quoin Pharmaceuticals | As of 31 August 2026, Quoin Pharmaceuticals estimated primary completion of a Phase 3 trial in Netherton Syndrome, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06953466 | |
| Clinical | Sellas Life Sciences Group | As of 3 September 2026, Sellas Life Sciences Group estimated primary completion of a Phase 2 trial in Hematologic Malignancies, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04588922 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 5 June 2026, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in asthma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05593250 | |
| Clinical | Shanghai Henlius Biotech | As of 17 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Colorectal Cancer (CRC), on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07106892 | |
| Clinical | Shanghai Jiaolian Drug Research and Development Co. | As of 14 August 2026, Shanghai Jiaolian Drug Research and Development Co. estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06447597 | |
| Clinical | Shionogi | As of 29 September 2026, Shionogi estimated primary completion of a Phase 2 trial in Respiratory Syncytial Virus Infections, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07214571 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Selected Subjects With Advanced Solid Tumors, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05631262 | |
| Clinical | Sunshine Lake Pharma Co. | As of 28 April 2026, Sunshine Lake Pharma Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05451602 | |
| Clinical | Supernus Pharmaceuticals | As of 30 August 2022, Supernus Pharmaceuticals estimated primary completion of a Phase 2 trial in Focal Impaired Awareness Seizures, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03474770 | |
| Clinical | Suzhou Abogen Biosciences Co. | As of 23 September 2026, Suzhou Abogen Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06088004 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 29 May 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Biliary Tract Cancer, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06465563 | |
| Clinical | Swedish Orphan Biovitrum | As of 15 September 2026, Swedish Orphan Biovitrum estimated primary completion of a Phase 2 trial in vEXAS, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06782373 | |
| Clinical | Teclison | As of 16 April 2026, Teclison estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03259867 | |
| Clinical | ThromBio Pty. | As of 25 November 2025, ThromBio Pty. estimated primary completion of a Phase 2 trial in Ischemic Stroke, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06813651 | |
| Clinical | Vertex Pharmaceuticals Incorporated | As of 5 May 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 2 trial in Proteinuric Kidney Disease, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06794996 | |
| Clinical | Wuhan Createrna Science and Technology Co. | As of 18 April 2025, Wuhan Createrna Science and Technology Co. estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria (PNH), on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06933914 | |
| Clinical | Xynomic Pharmaceuticals | As of 13 April 2025, Xynomic Pharmaceuticals estimated primary completion of a Phase 3 trial in Renal Cell Carcinoma, on 30 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03592472 | |
| Clinical | AMO Pharma | As of 28 May 2025, AMO Pharma estimated primary completion of a Phase 3 trial in Congenital Myotonic Dystrophy, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05004129 | |
| Clinical | AUG Therapeutics | As of 1 May 2026, AUG Therapeutics estimated primary completion of a Phase 3 trial in Leukocyte Adhesion Deficiency, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05754450 | |
| Clinical | Akeso | As of 9 March 2026, Akeso estimated primary completion of a Phase 2 trial in Advanced Malignant Tumors, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05229497 | |
| Clinical | Albireo, an Ipsen | As of 2 October 2026, Albireo, an Ipsen estimated primary completion of a Phase 3 trial in Alagille Syndrome, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05035030 | |
| Clinical | Allist Pharmaceuticals | As of 13 March 2026, Allist Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS P.G12C, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06008288 | |
| Clinical | Amicus Therapeutics | As of 6 July 2026, Amicus Therapeutics estimated primary completion of a Phase 3 trial in Fabry Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04020055 | |
| Clinical | Annexon | As of 28 May 2026, Annexon estimated primary completion of a Phase 3 trial in Guillain-Barre Syndrome, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07020819 | |
| Clinical | Ascentage Pharma Group | As of 18 June 2026, Ascentage Pharma Group estimated primary completion of a Phase 3 trial in cLL/SLL, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06104566 | |
| Clinical | AskGene Pharma | As of 27 January 2026, AskGene Pharma estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05867420 | |
| Clinical | Astellas Pharma Global Development | As of 18 June 2026, Astellas Pharma Global Development estimated primary completion of a Phase 2 trial in Pharmacokinetics of Zolbetuximab, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03505320 | |
| Clinical | AstraZeneca | As of 11 August 2026, AstraZeneca estimated primary completion of a Phase 3 trial in cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05303532 | |
| Clinical | Aveta Biomics | As of 5 October 2026, Aveta Biomics estimated primary completion of a Phase 2 trial in glioma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06011109 | |
| Clinical | Avistone Biotechnology Co. | As of 21 May 2025, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06343064 | |
| Clinical | Azure Biotech | As of 22 May 2026, Azure Biotech estimated primary completion of a Phase 2 trial in Vulvo Vaginal Atrophy (VVA), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06197568 | |
| Clinical | BeOne Medicines | As of 28 August 2026, BeOne Medicines estimated primary completion of a Phase 3 trial in B-cell Malignancies, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04170283 | |
| Clinical | Beijing Tuohua Weiye Biotechnology Co. | As of 17 February 2026, Beijing Tuohua Weiye Biotechnology Co. estimated primary completion of a Phase 2 trial in Decompensated Hepatitis B Cirrhosis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07413549 | |
| Clinical | Bio-Thera Solutions | As of 2 October 2026, Bio-Thera Solutions estimated primary completion of a Phase 2 trial in Dermatitis, Atopic, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06094179 | |
| Clinical | BioInvent International | As of 18 February 2026, BioInvent International estimated primary completion of a Phase 2 trial in Advanced Malignancies, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04752826 | |
| Clinical | Biocity Biopharmaceutics Co. | As of 17 February 2025, Biocity Biopharmaceutics Co. estimated primary completion of a Phase 3 trial in IgA Nephropathy (IgAN), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06819826 | |
| Clinical | Blueprint Medicines | As of 22 July 2026, Blueprint Medicines estimated primary completion of a Phase 2 trial in Chronic Inducible Urticaria, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06931405 | |
| Clinical | Boehringer Ingelheim | As of 1 October 2026, Boehringer Ingelheim estimated primary completion of a Phase 3 trial in Kidney Disease, Chronic, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06531824 | |
| Clinical | Chongqing Precision Biotech Co. | As of 25 February 2025, Chongqing Precision Biotech Co. estimated primary completion of a Phase 2 trial in b-ALL, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04781634 | |
| Clinical | Chongqing Precision Biotech Co. | As of 25 February 2025, Chongqing Precision Biotech Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04776330 | |
| Clinical | Chongqing Precision Biotech Co. | As of 25 February 2025, Chongqing Precision Biotech Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04271644 | |
| Clinical | Clarity Pharmaceuticals | As of 14 May 2026, Clarity Pharmaceuticals estimated primary completion of a Phase 3 trial in Prostate Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06970847 | |
| Clinical | Clearmind Medicine | As of 31 March 2026, Clearmind Medicine estimated primary completion of a Phase 2 trial in Alcohol Use Disorder, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05913752 | |
| Clinical | Cloudbreak Therapeutics | As of 24 September 2025, Cloudbreak Therapeutics estimated primary completion of a Phase 3 trial in pterygium, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05456425 | |
| Clinical | Corza Medical | As of 30 June 2026, Corza Medical estimated primary completion of a Phase 3 trial in hemorrhage, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06664775 | |
| Clinical | E-nitiate Biopharmaceuticals (Hangzhou) Co. | As of 17 July 2026, E-nitiate Biopharmaceuticals (Hangzhou) Co. estimated primary completion of a Phase 2 trial in Adult Subjects With Non-Segmental Vitiligo, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07712523 | |
| Clinical | ENCell | As of 26 May 2026, ENCell estimated primary completion of a Phase 2 trial in Charcot-Marie-Tooth Disease Type 1A, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06328712 | |
| Clinical | Eisai | As of 6 October 2026, Eisai estimated primary completion of a Phase 3 trial in Early Alzheimer's Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03887455 | |
| Clinical | Elixiron Immunotherapeutics (Hong Kong) | As of 5 June 2026, Elixiron Immunotherapeutics (Hong Kong) estimated primary completion of a Phase 2 trial in Non-segmental Vitiligo, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07223229 | |
| Clinical | Estrella Biopharma | As of 7 August 2025, Estrella Biopharma estimated primary completion of a Phase 2 trial in B-Cell Non-Hodgkin's Lymphoma (NHL), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06343311 | |
| Clinical | Evopoint Biosciences | As of 15 April 2026, Evopoint Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06799637 | |
| Clinical | Excelsior | As of 26 February 2025, Excelsior estimated primary completion of a Phase 2 trial in Alzheimer Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05413655 | |
| Clinical | Excyte Biopharma | As of 6 February 2026, Excyte Biopharma estimated primary completion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06580301 | |
| Clinical | Frantz Viral Therapeutics | As of 18 May 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Anal High-grade Squamous Intraepithelial Lesion, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06206564 | |
| Clinical | Galderma R&D | As of 24 August 2026, Galderma R&D estimated primary completion of a Phase 3 trial in Acne Vulgaris, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07186413 | |
| Clinical | GeneCradle | As of 5 June 2025, GeneCradle estimated primary completion of a Phase 3 trial in SMA - Spinal Muscular Atrophy, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06971094 | |
| Clinical | Genfleet Therapeutics (Shanghai) | As of 12 August 2025, Genfleet Therapeutics (Shanghai) estimated primary completion of a Phase 2 trial in Large B-cell Lymphoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06375733 | |
| Clinical | GeoVax | As of 11 February 2026, GeoVax estimated primary completion of a Phase 2 trial in COVID-19 Infection, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04977024 | |
| Clinical | Guangdong Hengrui Pharmaceutical Co. | As of 20 August 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in psoriasis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07719530 | |
| Clinical | Guangdong Hengrui Pharmaceutical Co. | As of 31 August 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Moderate to Severe Atopic Dermatitis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06468956 | |
| Clinical | Guangzhou Gloria Biosciences Co. | As of 16 December 2025, Guangzhou Gloria Biosciences Co. estimated primary completion of a Phase 3 trial in Multiple Myeloma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06514508 | |
| Clinical | Guangzhou JOYO Pharma Co. | As of 19 November 2024, Guangzhou JOYO Pharma Co. estimated primary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06125327 | |
| Clinical | Hangzhou Hanx Biopharmaceuticals | As of 15 January 2025, Hangzhou Hanx Biopharmaceuticals estimated primary completion of a Phase 2 trial in glioma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06703255 | |
| Clinical | Hangzhou Highlightll Pharmaceutical Co. | As of 25 September 2026, Hangzhou Highlightll Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Rheumatoid Arthritis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06887127 | |
| Clinical | Hillhurst Biopharmaceuticals | As of 21 September 2026, Hillhurst Biopharmaceuticals estimated primary completion of a Phase 2 trial in Parkinson Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07005180 | |
| Clinical | Hoffmann-La Roche | As of 16 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Crohns Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05910528 | |
| Clinical | Hoffmann-La Roche | As of 28 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Urothelial Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05645692 | |
| Clinical | Hoffmann-La Roche | As of 21 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05894239 | |
| Clinical | Hoffmann-La Roche | As of 11 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Solid Tumors, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT02320435 | |
| Clinical | Imbioray (Hangzhou) Biomedicine Co. | As of 2 July 2026, Imbioray (Hangzhou) Biomedicine Co. estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma (RCC), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07087158 | |
| Clinical | Impact Therapeutics | As of 1 April 2025, Impact Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05269316 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 17 November 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Thyroid Eye Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07113262 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 12 May 2026, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in overweight, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06884293 | |
| Clinical | Innovent Biologics Technology | As of 27 May 2026, Innovent Biologics Technology estimated primary completion of a Phase 2 trial in Diabetic Macular Oedema, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06908876 | |
| Clinical | Inovio Pharmaceuticals | As of 4 May 2026, Inovio Pharmaceuticals estimated primary completion of a Phase 2 trial in glioblastoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03491683 | |
| Clinical | Insmed Incorporated | As of 20 August 2026, Insmed Incorporated estimated primary completion of a Phase 3 trial in Pulmonary Arterial Hypertension, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05649748 | |
| Clinical | Iperboreal Pharma Srl | As of 24 March 2026, Iperboreal Pharma Srl estimated primary completion of a Phase 3 trial in End Stage Renal Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03994471 | |
| Clinical | JCR Pharmaceuticals Co. | As of 8 September 2026, JCR Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Mucopolysaccharidosis II, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03708965 | |
| Clinical | Jacobio Pharmaceuticals Co. | As of 20 January 2026, Jacobio Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06959615 | |
| Clinical | Janssen Research & Development | As of 1 October 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT01804686 | |
| Clinical | Jazz Pharmaceuticals | As of 10 July 2026, Jazz Pharmaceuticals estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06695845 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 22 September 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Neuromuscular Blockade, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07746726 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 17 July 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06413745 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 22 August 2025, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05424835 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 31 December 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04691804 | |
| Clinical | Kamau Therapeutics | As of 2 July 2026, Kamau Therapeutics estimated primary completion of a Phase 2 trial in Sickle Cell Disease, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04819841 | |
| Clinical | Kartos Therapeutics | As of 25 September 2025, Kartos Therapeutics estimated primary completion of a Phase 3 trial in myelofibrosis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06479135 | |
| Clinical | Klus Pharma | As of 17 September 2026, Klus Pharma estimated primary completion of a Phase 2 trial in Epithelial Ovarian Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04152499 | |
| Clinical | Laboratorios Silanes S.A. de C.V. | As of 3 April 2025, Laboratorios Silanes S.A. de C.V. estimated primary completion of a Phase 3 trial in Gout Arthritis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06863701 | |
| Clinical | Lin BioScience | As of 27 March 2026, Lin BioScience estimated primary completion of a Phase 2 trial in Relapsed or Resistant Acute Leukaemias, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05756322 | |
| Moved from 21 Aug 2026 | Clinical | Longboard Pharmaceuticals | As of 17 September 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Dravet Syndrome, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06660394 |
| Clinical | Lukas Biomedical | As of 6 March 2025, Lukas Biomedical estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05304481 | |
| Clinical | Lumosa Therapeutics Co. | As of 31 August 2026, Lumosa Therapeutics Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05198323 | |
| Clinical | Mabwell (Shanghai) Bioscience Co. | As of 19 September 2024, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in Advanced Urothelial Carcinoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06079112 | |
| Clinical | Mapi Pharma | As of 1 May 2026, Mapi Pharma estimated primary completion of a Phase 2 trial in schizophrenia, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07185815 | |
| Clinical | Materia Medica Holding | As of 13 February 2026, Materia Medica Holding estimated primary completion of a Phase 3 trial in Cystitis Chronic, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06284265 | |
| Clinical | MediciNova | As of 5 February 2026, MediciNova estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05464784 | |
| Clinical | Mercator MedSystems | As of 25 September 2026, Mercator MedSystems estimated primary completion of a Phase 2 trial in Thrombosis, Deep Vein, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04862468 | |
| Clinical | Miltenyi Biomedicine | As of 13 July 2026, Miltenyi Biomedicine estimated primary completion of a Phase 2 trial in Refractory Diffuse Large B Cell Lymphoma (DLBCL), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04792489 | |
| Clinical | NaviFUS | As of 9 April 2026, NaviFUS estimated primary completion of a Phase 3 trial in Glioblastoma Multiforme, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06496971 | |
| Clinical | NaviFUS | As of 9 April 2026, NaviFUS estimated primary completion of a Phase 2 trial in Drug Resistant Epilepsy, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06388707 | |
| Clinical | Olatec Therapeutics | As of 11 March 2026, Olatec Therapeutics estimated primary completion of a Phase 3 trial in Acute Gout Flare, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05658575 | |
| Clinical | OncoC4 | As of 14 September 2026, OncoC4 estimated primary completion of a Phase 2 trial in Non Small Cell Lung Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04140526 | |
| Clinical | Ono Pharmaceutical Co. | As of 25 September 2026, Ono Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Agitation Associated With Alzheimer's Disease Dementia, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06803823 | |
| Clinical | Ono Pharmaceutical Co. | As of 3 June 2025, Ono Pharmaceutical Co. estimated primary completion of a Phase 2 trial in pan-tumor, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04566380 | |
| Clinical | Partner Therapeutics | As of 29 April 2025, Partner Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumours Harboring NRG1 Fusion, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT02912949 | |
| Clinical | Pell Bio-Med Technology Co. | As of 9 October 2026, Pell Bio-Med Technology Co. estimated primary completion of a Phase 2 trial in Diffuse Large B Cell Lymphoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05326243 | |
| Clinical | Pfizer | As of 25 November 2025, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05226871 | |
| Clinical | Pfizer | As of 22 June 2026, Pfizer estimated primary completion of a Phase 3 trial in Advanced Malignancies, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05059522 | |
| Clinical | Pfizer | As of 6 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04553133 | |
| Clinical | Pfizer | As of 6 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06125522 | |
| Clinical | RemeGen Co. | As of 18 December 2023, RemeGen Co. estimated primary completion of a Phase 3 trial in Urothelial Carcinoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05302284 | |
| Clinical | RemeGen Co. | As of 9 April 2026, RemeGen Co. estimated primary completion of a Phase 3 trial in Myasthenia Gravis, Ocular, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07249632 | |
| Clinical | Rhizen Pharmaceuticals SA | As of 2 December 2025, Rhizen Pharmaceuticals SA estimated primary completion of a Phase 2 trial in Triple Negative Breast Cancer (TNBC), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06189209 | |
| Clinical | Sano Chemicals | As of 15 June 2026, Sano Chemicals estimated primary completion of a Phase 2 trial in Candidiasis, Vulvovaginal, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07521137 | |
| Clinical | Sarepta Therapeutics | As of 5 October 2026, Sarepta Therapeutics estimated primary completion of a Phase 2 trial in Myotonic Dystrophy 1, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06138743 | |
| Clinical | ScinnoHub Pharmaceutical Co. | As of 15 December 2025, ScinnoHub Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Total Knee Arthroplasty, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07127042 | |
| Clinical | Serum Institute of India Pvt. | As of 29 June 2026, Serum Institute of India Pvt. estimated primary completion of a Phase 3 trial in Human Papillomavirus Infection, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06281119 | |
| Clinical | Shanghai Cell Therapy Group Co. | As of 28 August 2025, Shanghai Cell Therapy Group Co. estimated primary completion of a Phase 2 trial in Solid Tumor Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07146672 | |
| Clinical | Shanghai Henlius Biotech | As of 22 April 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Cervical Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06769152 | |
| Clinical | Shanghai Jiaolian Drug Research and Development Co. | As of 5 May 2026, Shanghai Jiaolian Drug Research and Development Co. estimated primary completion of a Phase 3 trial in pemphigus, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06454357 | |
| Clinical | Shanghai Jiaolian Drug Research and Development Co. | As of 5 May 2026, Shanghai Jiaolian Drug Research and Development Co. estimated primary completion of a Phase 3 trial in Primary Membranous Nephropathy, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06470191 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 5 May 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06214143 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 6 August 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05944224 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 5 May 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Breast Cancer Brain Metastases, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05872347 | |
| Clinical | Shanghai RAAS Blood Products Co. | As of 12 June 2026, Shanghai RAAS Blood Products Co. estimated primary completion of a Phase 2 trial in Hemophilia A, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07644832 | |
| Clinical | Shanghai Synvida Biotechnology Co. | As of 11 February 2026, Shanghai Synvida Biotechnology Co. estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis(IPF), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07121413 | |
| Clinical | Shenyang Sunshine Pharmaceutical Co. | As of 3 August 2025, Shenyang Sunshine Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Locally Advanced, Recurrent or Metastatic Malignancies, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07022002 | |
| Clinical | Shionogi | As of 6 May 2026, Shionogi estimated primary completion of a Phase 2 trial in Sleep Apnea, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06776432 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06081959 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05265091 | |
| Clinical | Skingenix | As of 16 March 2026, Skingenix estimated primary completion of a Phase 2 trial in burns, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT01297400 | |
| Clinical | Spirovant Sciences | As of 25 November 2024, Spirovant Sciences estimated primary completion of a Phase 2 trial in Cystic Fibrosis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06526923 | |
| Clinical | Supergene | As of 1 December 2025, Supergene estimated primary completion of a Phase 3 trial in Acute Limb Ischemia, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05372718 | |
| Clinical | Supernus Pharmaceuticals | As of 24 March 2026, Supernus Pharmaceuticals estimated primary completion of a Phase 2 trial in Major Depressive Disorder (MDD), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07226661 | |
| Clinical | TRB Chemedica | As of 30 September 2026, TRB Chemedica estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04318041 | |
| Clinical | TaiRx | As of 13 April 2026, TaiRx estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05257590 | |
| Clinical | Takeda | As of 2 March 2026, Takeda estimated primary completion of a Phase 3 trial in cytomegalovirus (CMV), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06439342 | |
| Clinical | Tarsus Pharmaceuticals | As of 2 March 2026, Tarsus Pharmaceuticals estimated primary completion of a Phase 2 trial in Ocular Rosacea, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07443202 | |
| Clinical | Tasly Pharmaceutical Group Co. | As of 20 January 2026, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Postprandial Distress Syndrome, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06696261 | |
| Clinical | Tasly Pharmaceutical Group Co. | As of 9 January 2026, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Coronary Artery Bypass Grafting (CABG), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07265349 | |
| Clinical | TheiaNova | As of 4 February 2026, TheiaNova estimated primary completion of a Phase 2 trial in keratoconus, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07388069 | |
| Clinical | Tioga Pharmaceuticals | As of 9 September 2025, Tioga Pharmaceuticals estimated primary completion of a Phase 2 trial in Vasomotor Symptoms, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07042516 | |
| Clinical | Valenta Pharm JSC | As of 10 July 2025, Valenta Pharm JSC estimated primary completion of a Phase 2 trial in Pharyngitis Acute, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06843018 | |
| Clinical | Valenta Pharm JSC | As of 11 July 2025, Valenta Pharm JSC estimated primary completion of a Phase 2 trial in Chronic Cholecystitis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06842966 | |
| Moved from 31 Oct 2026 | Clinical | Viatris Innovation | As of 15 September 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05672576 |
| Clinical | Vir Biotechnology | As of 8 April 2026, Vir Biotechnology estimated primary completion of a Phase 3 trial in Viral Hepatitis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06903338 | |
| Clinical | VivaVision Biotech | As of 24 August 2026, VivaVision Biotech estimated primary completion of a Phase 3 trial in Non-infectious Anterior Uveitis, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07136805 | |
| Clinical | Xenothera | As of 20 August 2026, Xenothera estimated primary completion of a Phase 2 trial in Peripheral T Cells Lymphoma (PTCL), on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06495723 | |
| Clinical | XyloCor Therapeutics | As of 3 August 2025, XyloCor Therapeutics estimated primary completion of a Phase 2 trial in Refractory Angina, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07048808 | |
| Clinical | Zhejiang ACEA Pharmaceutical Co. | As of 15 August 2025, Zhejiang ACEA Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Relapsed or Refractory Multiple Myeloma, on 31 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05565807 | |
| Clinical | A. Menarini International Licensing | As of 9 June 2026, A. Menarini International Licensing estimated primary completion of a Phase 3 trial in Mixed Dyslipidemia, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07614958 | |
| Clinical | AION Healthspan | As of 1 April 2026, AION Healthspan estimated primary completion of a Phase 2 trial in Chronic Kidney Disease Stage 3, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06721143 | |
| Clinical | AbbVie | As of 22 September 2026, AbbVie estimated primary completion of a Phase 3 trial in Hepatocellular Carcinoma, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06109272 | |
| Clinical | AbbVie | As of 23 February 2026, AbbVie estimated primary completion of a Phase 3 trial in Atopic Dermatitis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06701331 | |
| Clinical | Actio Biosciences | As of 7 August 2026, Actio Biosciences estimated primary completion of a Phase 2 trial in KCNT1-Related Epilepsy, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07600736 | |
| Clinical | Adneuris Therapeutics | As of 30 September 2026, Adneuris Therapeutics estimated primary completion of a Phase 3 trial in pain, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07845071 | |
| Clinical | Akeso | As of 14 November 2024, Akeso estimated primary completion of a Phase 3 trial in Head and Neck Squamous Cell Carcinoma, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06601335 | |
| Clinical | Alesta Therapeutics | As of 3 August 2026, Alesta Therapeutics estimated primary completion of a Phase 2 trial in hypophosphatasia (HPP), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07179640 | |
| Clinical | Arcus Biosciences | As of 29 September 2026, Arcus Biosciences estimated primary completion of a Phase 2 trial in Gastrointestinal Tract Malignancies, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05329766 | |
| Clinical | BioMendics | As of 13 August 2026, BioMendics estimated primary completion of a Phase 2 trial in Epidermolysis Bullosa Simplex, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07027345 | |
| Clinical | Biocad | As of 8 July 2025, Biocad estimated primary completion of a Phase 3 trial in Melanoma Stage III, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05751928 | |
| Clinical | Biocad | As of 19 September 2025, Biocad estimated primary completion of a Phase 2 trial in Ulcerative Colitis (UC), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07080034 | |
| Clinical | Biotheus | As of 9 July 2026, Biotheus estimated primary completion of a Phase 2 trial in Neuroendocrine Neoplasm, on 1 January 2027. | Estimated | ClinicalTrials.gov registration: NCT05879055 | |
| Clinical | CStone Pharmaceuticals | As of 20 August 2026, CStone Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06741644 | |
| Clinical | Caravel Oculus Pty | As of 6 August 2026, Caravel Oculus Pty estimated primary completion of a Phase 2 trial in Corneal Endothelial Cell Loss, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07694375 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 10 September 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Breast Cancer, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06561607 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 31 December 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Thyroid Cancer, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06860971 | |
| Clinical | Colgate Palmolive | As of 25 September 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in plaque, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07842991 | |
| Clinical | Coya Therapeutics | As of 6 August 2026, Coya Therapeutics estimated primary completion of a Phase 3 trial in Amyotrophic Lateral Sclerosis (ALS), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07161999 | |
| Clinical | Cumberland Pharmaceuticals | As of 5 March 2026, Cumberland Pharmaceuticals estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05571059 | |
| Clinical | Dr. F. Köhler Chemie | As of 30 January 2026, Dr. F. Köhler Chemie estimated primary completion of a Phase 2 trial in Heart Transplantation, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06032195 | |
| Clinical | Edgewise Therapeutics | As of 12 November 2025, Edgewise Therapeutics estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05540860 | |
| Clinical | Eledon Pharmaceuticals | As of 29 June 2025, Eledon Pharmaceuticals estimated primary completion of a Phase 2 trial in Prevention of Rejection in Kidney Transplant, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05027906 | |
| Clinical | EyeD Pharma | As of 30 July 2026, EyeD Pharma estimated primary completion of a Phase 2 trial in glaucoma, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07036510 | |
| Clinical | Gilead Sciences | As of 11 September 2026, Gilead Sciences estimated primary completion of a Phase 2 trial in Ulcerative Colitis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06029972 | |
| Clinical | Hanmi Pharmaceutical Company | As of 8 April 2026, Hanmi Pharmaceutical Company estimated primary completion of a Phase 2 trial in obese, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07205900 | |
| Clinical | Hope Biosciences Research Foundation | As of 20 November 2025, Hope Biosciences Research Foundation estimated primary completion of a Phase 2 trial in Relapsing Remitting Multiple Sclerosis (RRMS), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06800404 | |
| Clinical | Hyundai Bioscience Co. | As of 10 July 2026, Hyundai Bioscience Co. estimated primary completion of a Phase 3 trial in dengue, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07576868 | |
| Clinical | Imvax | As of 9 July 2026, Imvax estimated primary completion of a Phase 2 trial in glioblastoma, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT04485949 | |
| Clinical | Jacobio Pharmaceuticals Co. | As of 22 May 2026, Jacobio Pharmaceuticals Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06386146 | |
| Clinical | Lakewood-Amedex | As of 2 September 2026, Lakewood-Amedex estimated primary completion of a Phase 2 trial in Diabetic Foot Ulcers (DFUs), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07565506 | |
| Clinical | Larimar Therapeutics | As of 9 October 2026, Larimar Therapeutics estimated primary completion of a Phase 2 trial in Friedreich Ataxia, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06447025 | |
| Clinical | Lexicon Pharmaceuticals | As of 26 August 2026, Lexicon Pharmaceuticals estimated primary completion of a Phase 3 trial in Obstructive Cardiomyopathy, Hypertrophic, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06481891 | |
| Clinical | LigaChem Biosciences | As of 24 September 2025, LigaChem Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05941507 | |
| Clinical | Loxo Oncology | As of 15 May 2026, Loxo Oncology estimated primary completion of a Phase 3 trial in Lymphoma, Mantle-Cell, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT04662255 | |
| Clinical | Marengo Therapeutics | As of 24 September 2025, Marengo Therapeutics estimated primary completion of a Phase 2 trial in Triple Negative Locally Advanced Non-resectable Breast Cancer, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06827613 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 18 June 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07208773 | |
| Clinical | Mirum Pharmaceuticals | As of 25 August 2026, Mirum Pharmaceuticals estimated primary completion of a Phase 2 trial in Primary Biliary Cholangitis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05050136 | |
| Clinical | Newleos Therapeutics | As of 9 July 2026, Newleos Therapeutics estimated primary completion of a Phase 2 trial in Social Anxiety Disorder (SAD), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07323784 | |
| Clinical | OncoVerity | As of 11 May 2026, OncoVerity estimated primary completion of a Phase 2 trial in Leukemia, Myeloid, Acute, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06384261 | |
| Clinical | Praxis Precision Medicines | As of 3 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Focal Epilepsy, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07505004 | |
| Clinical | Prolium Bioscience | As of 9 October 2026, Prolium Bioscience estimated primary completion of a Phase 2 trial in Healthy Volunteers, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07641634 | |
| Clinical | QBiotics Group | As of 12 March 2026, QBiotics Group estimated primary completion of a Phase 2 trial in Soft Tissue Sarcoma, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05755113 | |
| Clinical | QED Therapeutics, a BridgeBio | As of 16 July 2026, QED Therapeutics, a BridgeBio estimated primary completion of a Phase 3 trial in hypochondroplasia, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06873035 | |
| Clinical | Qilu Pharmaceutical Co. | As of 14 July 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07062978 | |
| Clinical | Rempex | As of 10 September 2026, Rempex estimated primary completion of a Phase 2 trial in Acute Pyelonephritis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06672978 | |
| Clinical | Resilience | As of 3 April 2026, Resilience estimated primary completion of a Phase 3 trial in cancer, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06867705 | |
| Clinical | SIGA Technologies | As of 14 September 2026, SIGA Technologies estimated primary completion of a Phase 2 trial in smallpox, on 1 January 2027. | Estimated | ClinicalTrials.gov registration: NCT04957485 | |
| Clinical | Second Life Therapeutics | As of 15 September 2026, Second Life Therapeutics estimated primary completion of a Phase 2 trial in Head & Neck Cancer, on 1 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07341737 | |
| Clinical | Sensory Cloud | As of 9 September 2026, Sensory Cloud estimated primary completion of a Phase 2 trial in Refractory Chronic Cough and Unexplained Chronic Cough, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07690059 | |
| Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. | As of 3 March 2026, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Port-wine Birthmarks, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05171894 | |
| Clinical | Shanghai Henlius Biotech | As of 18 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Membranous Nephropathy, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07038382 | |
| Clinical | Sinovac Biotech Co. | As of 10 August 2026, Sinovac Biotech Co. estimated primary completion of a Phase 3 trial in Epidemic Meningitis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07505836 | |
| Clinical | Skyline Therapeutics (US) | As of 28 August 2026, Skyline Therapeutics (US) estimated primary completion of a Phase 2 trial in Neovascular Age-related Macular Degeneration, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05986864 | |
| Clinical | Sun Pharmaceutical Industries | As of 22 April 2026, Sun Pharmaceutical Industries estimated primary completion of a Phase 3 trial in Actinic Keratosis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07144345 | |
| Clinical | Sun Pharmaceutical Industries | As of 22 April 2026, Sun Pharmaceutical Industries estimated primary completion of a Phase 3 trial in Actinic Keratosis, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07144852 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 1 May 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07298772 | |
| Clinical | Synendos Therapeutics | As of 18 June 2026, Synendos Therapeutics estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07478744 | |
| Clinical | Telix Pharmaceuticals (Innovations) Pty | As of 23 July 2026, Telix Pharmaceuticals (Innovations) Pty estimated primary completion of a Phase 3 trial in pCA, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07052214 | |
| Clinical | Ultragenyx Pharmaceutical | As of 28 September 2026, Ultragenyx Pharmaceutical estimated primary completion of a Phase 3 trial in Osteogenesis Imperfecta, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06636071 | |
| Clinical | Vaderis Therapeutics | As of 17 March 2026, Vaderis Therapeutics estimated primary completion of a Phase 2 trial in Hereditary Hemorrhagic Telangiectasia (HHT), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05406362 | |
| Moved from 1 Dec 2026 | Clinical | Vantive Health | As of 5 October 2026, Vantive Health estimated primary completion of a Phase 3 trial in Regional Citrate Anticoagulation (RCA), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT05399537 |
| Clinical | Vaxcyte | As of 15 May 2026, Vaxcyte estimated primary completion of a Phase 3 trial in Pneumococcal Vaccines, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT07284654 | |
| Clinical | Xenon Pharmaceuticals | As of 3 September 2026, Xenon Pharmaceuticals estimated primary completion of a Phase 3 trial in Major Depressive Disorder, in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06922110 | |
| Clinical | iOnctura | As of 16 January 2026, iOnctura estimated primary completion of a Phase 2 trial in Non-Squamous Non-Small Cell Lung Cancer (NSCLC), in January 2027. | Estimated | ClinicalTrials.gov registration: NCT06879717 | |
| Clinical | Shenzhen Kangzhe Biotechnology Co. | As of 11 March 2026, Shenzhen Kangzhe Biotechnology Co. estimated primary completion of a Phase 2 trial in Uterine Fibroids With Menorrhagia, on 3 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07402369 |
Week of 4 January 2027
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AstraZeneca | As of 16 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Heterozygous Familial Hypercholesterolaemia, on 4 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07000136 | |
| Clinical | Merck Sharp & Dohme | As of 27 February 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Gastroesophageal Cancer, on 4 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06356311 | |
| Moved from 15 Jan 2027 | Clinical | MoonLake Immunotherapeutics | As of 9 October 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Arthritis, Psoriatic, on 4 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06641089 |
| Clinical | Hangzhou Sciwind Biosciences Co. | As of 16 September 2026, Hangzhou Sciwind Biosciences Co. estimated primary completion of a Phase 2 trial in Overweight and/or Obesity, on 5 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07243171 | |
| Clinical | Amgen | As of 10 August 2026, Amgen estimated primary completion of a Phase 2 trial in Thyroid Eye Disease, on 6 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06401044 | |
| Clinical | AstraZeneca | As of 30 September 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Systemic Sclerosis, on 6 January 2027. | Estimated | ClinicalTrials.gov registration: NCT05925803 | |
| Clinical | Bristol-Myers Squibb | As of 18 August 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Anemia, Sickle Cell, on 6 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06481306 | |
| Clinical | Incyte | As of 10 August 2026, Incyte estimated primary completion of a Phase 2 trial in Chronic Graft-versus-host-disease, on 6 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06843408 | |
| Clinical | Norgine | As of 7 October 2026, Norgine estimated primary completion of a Phase 3 trial in Bowel Cleansing Prior to Clinical Procedures, on 6 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07218523 | |
| Clinical | Sanofi | As of 15 April 2026, Sanofi estimated primary completion of a Phase 3 trial in Sickle Cell Disease, on 7 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07247188 | |
| Clinical | Ocular Therapeutix | As of 17 June 2025, Ocular Therapeutix estimated primary completion of a Phase 3 trial in Neovascular Age-related Macular Degeneration, on 8 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06495918 | |
| Clinical | Sanofi | As of 23 February 2026, Sanofi estimated primary completion of a Phase 2 trial in Plasma Cell Myeloma Refractory, on 8 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06356571 | |
| Clinical | Shanghai Fosun Pharmaceutical Industrial Development Co. | As of 25 September 2026, Shanghai Fosun Pharmaceutical Industrial Development Co. estimated primary completion of a Phase 2 trial in Non-Cystic Fibrosis Bronchiectasis, on 8 January 2027. | Estimated | ClinicalTrials.gov registration: NCT06981091 | |
| Clinical | GeneQuantum Healthcare (Suzhou) Co. | As of 29 June 2026, GeneQuantum Healthcare (Suzhou) Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, on 9 January 2027. | Estimated | ClinicalTrials.gov registration: NCT07673029 |
What this does not cover
The calendar reads government registers and nothing else. It has no view of anything a company has not filed, and no free source publishes pending FDA goal dates, so approval decision dates are absent by construction rather than by omission. An empty week is not evidence that nothing is scheduled that week. Read a gap as a gap in the registers.
Complete response letters are never published here. Neither are live offerings. Both exclusions are deliberate and permanent. The methodology page sets out every source, every gate and the current drop rate.
How it is compiled
Rows are written automatically from primary documents once a day. Nobody reviews each row before it appears. Every sentence is composed from structured fields taken out of the filing, never from the wording of the source, and each one carries the date on which the claim was made so it stays true after a date slips.
Not investment advice
Nothing here is a recommendation to buy or sell anything, and none of it is tailored to any reader. This page is identical for every visitor. It reports what public registers say, and public registers are wrong often enough that you should check the linked document before you act on a row.
Corrections and takedown
Write to [email protected] with the reference identifier of the row. Corrections and takedown requests are answered within two business days. No call is needed and none will be asked for.
When a row changes
A row whose date moves keeps its identity and gains a note saying where it moved from, so a calendar subscription updates the event in place instead of adding a second one. A withdrawn row stays visible for 30 days, struck through, and is listed on the changes page. Nothing disappears without a record.
Citing this page
Willard, J. Biotech catalyst calendar. julienwillard.com/calendar, as of 11 October 2026, 12:05 UTC. Licensed CC BY 4.0.